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I. INTRODUCTION 
The multinational effort to sequence the human genome 
was one of the most ambitious scientific undertakings in 
history and has been compared to the Apollo manned space 
program, the Lewis and Clark expedition, and the Manhattan 
Project.1 When completed, the Human Genome Project (HGP), 
which spanned fifteen years2 and involved over a thousand 
scientists worldwide, was heralded by President Bill Clinton as 
“an epoch-making triumph of science and reason.”3 It led to the 
publication of the first complete human DNA sequence and has 
resulted in major advances in biochemistry, bioinformatics, and 
genetics.4 The project also generated vast quantities of data 
about the genetic make-up of humans and other organisms, 
which reside in public databases that are available to any 
researcher in the world, creating what I refer to as the “genome 
commons.”5 But, in some respects, even more remarkable than 
                                                          
 1. E.g., ARTHUR M. LESK, INTRODUCTION TO GENOMICS 22 (2007); 
FRANCIS S. COLLINS, THE LANGUAGE OF LIFE 2 (2010); VICTOR K. MCELHENY, 
DRAWING THE MAP OF LIFE – INSIDE THE HUMAN GENOME PROJECT at ix 
(2010); James D. Watson, The Human Genome Project: Past, Present and 
Future, 248 SCIENCE 44, 44 (1990). 
 2. Planning for the HGP began in 1988 and is generally agreed to have 
concluded in 2002, though work continues to refine the human genomic map. 
See, e.g., Jeffrey M. Kidd et al., Mapping and Sequencing of Structural 
Variation from Eight Human Genomes, 453 NATURE 56 (2008); Watson, supra 
note 1, at 46; Major Events in the U.S. Human Genome Project and Related 
Projects, U.S. DEPARTMENT OF ENERGY GENOME PROGRAM, 
http://www.ornl.gov/sci/techresources/Human_Genome/project/timeline.shtml 
(last visited Oct. 28, 2010). 
 3. Reading the Book of Life: White House Remarks on Decoding of 
Genome, N.Y. TIMES, June 27, 2000, at F8. 
 4. See generally Francis Collins, Opinion: Has the Revolution Arrived?, 
464 NATURE 674 (2010) (describing the “profound impact on scientific 
progress” achieved by the HGP); International Human Genome Sequencing 
Consortium, Initial Sequencing and Analysis of the Human Genome, 409 
NATURE 860, 911–13 (2001) [hereinafter HGP Initial Paper] (discussing the 
impact the HGP has had on scientists’ ability to find disease genes and drug 
targets). 
 5. Jorge L. Contreras, Prepublication Data Release, Latency, and Genome 
Commons, 329 SCIENCE 393, 393 (2010) [hereinafter Contreras, Prepublication 
Data Release]. The term “commons” derives from the traditional designation of 
shared physical resources such as fields, pastures and forests, but has more 
recently been applied to intangibles and information, including aggregations of 
scientific data. See, e.g., Charlotte Hess & Elinor Ostrom, Introduction: An 
Overview of the Knowledge Commons, in UNDERSTANDING KNOWLEDGE AS A 
COMMONS: FROM THEORY TO PRACTICE 4, 12 (Charlotte Hess & Elinor Ostrom 
eds., 2006) (discussing the evolution of the term “commons”); Michael J. 
Madison, Brett M. Frischmann & Katherine J. Strandburg, Constructing 
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the impressive quantity of data generated by the HGP is the 
speed at which that data has been released to the public. 
At a 1996 summit in Bermuda, still early in the HGP, 
leaders of the scientific community agreed on a groundbreaking 
set of principles requiring that all DNA sequence data be 
released in publicly-accessible databases within twenty-four 
hours after generation.6 These “Bermuda Principles”7 
                                                          
Commons in the Cultural Environment, 95 CORNELL L. REV. 657, 659 (2010) 
[hereinafter Cultural Commons] (discussing the governance of cultural and 
scientific knowledge “commons”); Jorge L. Contreras, Data Sharing, Latency 
Variables and Science Commons, 25 BERKELEY TECH. L.J. (forthcoming 2010) 
[hereinafter Contreras, Data Sharing] (discussing the challenges of creating 
scientific knowledge commons). 
 6. Summary of Principles Agreed at the First International Strategy 
Meeting on Human Genome Sequencing, U.S. DEPARTMENT OF ENERGY 
GENOME PROGRAM, 
http://www.ornl.gov/sci/techresources/Human_Genome/research/bermuda.sht
ml (last visited Oct 28, 2010) [hereinafter Bermuda Principles] (reproducing 
the original report by the Human Genome Organisation (HUGO)). The text of 
the Bermuda Principles, as reported by the Human Genome Organisation 
(HUGO), reads, in pertinent part, as follows: 
Primary Genomic Sequence Should be in the Public Domain 
It was agreed that all human genomic sequence information, 
generated by centres funded for large-scale human sequencing, 
should be freely available and in the public domain in order to 
encourage research and development and to maximise its benefit to 
society. 
Primary Genomic Sequence Should be Rapidly Released 
• Sequence assemblies should be released as soon as possible; 
in some centres, assemblies of greater than 1 Kb would be 
released automatically on a daily basis. 
• Finished annotated sequence should be submitted 
immediately to the public databases. 
It was agreed that these principles should apply for all human 
genomic sequence generated by large-scale sequencing centres, 
funded for the public good, in order to prevent such centres 
establishing a privileged position in the exploitation and control of 
human sequence information. 
The text of the Bermuda Principles contained in a recent National Research 
Council report appears to reproduce an earlier, unapproved draft of the 
Bermuda Principles that contains the apocryphal sentence “[i]t was also 
agreed that patents should not be sought.” NATIONAL RESEARCH COUNCIL, 
REAPING THE BENEFITS OF GENOMIC AND PROTEOMIC RESEARCH 57, box C 
(2006) [hereinafter NRC – GENOMIC AND PROTEOMIC RESEARCH]. It is the 
author’s understanding, based on conversations with attendees at the original 
Bermuda meeting, that this sentence was deleted prior to final approval and 
does not form part of the generally-accepted text of the Bermuda Principles. 
Its significance, however, is discussed infra Section III.B. 
 7. These principles are referred to variously in the literature as the 
Bermuda Principles, the Bermuda Agreement, the Bermuda Resolution, the 
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contravened the typical practice in the sciences of making 
experimental data available only after publication8 and were 
praised by many including President Clinton, who urged “all 
nations, scientists and corporations to adopt this policy and 
honor its spirit.”9 The Bermuda Principles represent a 
significant achievement of private ordering in shaping the 
practices of an entire industry and establishing a global 
knowledge resource for the advancement of science. They 
continue to shape the data release practices of the genomics 
research community and have established rapid pre-publication 
data release as the norm in this and other fields.10 In this 
                                                          
Bermuda Rules, the Bermuda Protocol and the Bermuda Accord. For the sake 
of consistency, I will use the term “Bermuda Principles” throughout this 
paper. 
 8. Prior to the adoption of the Bermuda Principles (and to this day in 
fields outside of genomics), the data release policies of most government-
funded projects allowed researchers to retain their data privately until 
publication of results or for some specified “exclusivity period”, usually in the 
neighborhood of one year. See, e.g., NATIONAL ACADEMY OF SCIENCES, 
ENSURING THE INTEGRITY, ACCESSIBILITY, AND STEWARDSHIP OF RESEARCH 
DATA IN THE DIGITAL AGE 64 (2009) [hereinafter NAS – RESEARCH DATA] 
(noting that NASA and the European Southern Observatory Administration 
impose a 12-month proprietary periods and the U.S. National Optical 
Astronomy Observatory imposes an 18-month proprietary period on the 
release of data); NATIONAL RESEARCH COUNCIL, SHARING PUBLICATION-
RELATED DATA AND MATERIALS: RESPONSIBILITIES OF AUTHORSHIP IN THE 
LIFE SCIENCES 75 (2003) [hereinafter NRC – SHARING PUBLICATION-RELATED 
DATA] (describing the one-year “hold allowance” on the deposition of 
crystallography data into the Protein Data Bank); NATIONAL RESEARCH 
COUNCIL, BITS OF POWER – ISSUES IN GLOBAL ACCESS TO SCIENTIFIC DATA 
80–82 (1997) (describing data release policies of NASA and Global Change 
Research Program); J.H. Reichman & Paul F. Uhlir, A Contractually 
Reconstructed Research Commons for Scientific Data in a Highly Protectionist 
Intellectual Property Environment, 66 LAW & CONTEMP. PROBS. 315, 335 
(2003) (“[i]n most cases, publication of research results marks the point at 
which data produced by government-funded investigators should become 
generally available”). 
 9. JAMES SHREEVE, THE GENOME WAR 322 (2004) (quoting President 
Clinton). 
 10. See, e.g., Collins, supra note 4, at 675 (referring to the “radical ethic of 
immediate data deposit” adopted by the HGP as the current “norm for other 
community research projects”); Jane Kaye et al., Data Sharing in Genomics – 
Re-shaping Scientific Practice, 10 NATURE REV. GENETICS 331, 332 box 1 
(2009) (“[t]hese policies have created a climate in which data sharing has 
become the default, and [grant] applicants must demonstrate why their data 
should be exempt from the requirement that it should be deposited for use by 
other scientists”); Nikos Kyrpides, Fifteen Years of Microbial Genomics: 
Meeting the Challenges and Fulfilling the Dream, 27 NATURE BIOTECHNOLOGY 
627, 627 (2009) (“[o]ver time, as the substantial benefits of prepublication 
release of genome data have been recognized, many funding agencies and most 
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paper, I offer the first systematic analysis of the social, legal, 
and political factors that led to the adoption of the Bermuda 
Principles and the evolution of genomic data release policies 
over the past two decades. 
At the outset of the HGP, policy makers realized that it 
was necessary to develop efficient systems for coordinating 
activity among the geographically dispersed laboratories 
working on the massive project. But project coordination was 
not the only factor justifying the unorthodox rapid-release 
requirement of the Bermuda Principles.11 Rather, this 
revolutionary approach arose from the belief of several project 
leaders, both scientists and policy makers, that rapid release of 
the project’s genomic data was desirable for the advancement of 
scientific discovery and the consequent improvement of human 
health.12 Two distinct policy rationales thus emerged to support 
the rapid data release principles of Bermuda: (1) project 
coordination and (2) scientific advancement. Coupled with 
these, however, was a third distinct policy rationale for rapid 
data release: (3) minimizing encumbrances of DNA sequence 
data by patents.13 While this policy objective was seldom stated 
explicitly, it reflects a current that runs through many of the 
early (and recent) debates regarding data release. 
After the HGP completed its work, the rapid data release 
principles adopted in Bermuda were exported to other projects 
involving genomic and related technologies.14 Advances in 
science and technology, however, together with increasingly 
                                                          
of the large sequencing centers now adhere to the rapid data release policy set 
forth as the Bermuda Principles in 1996 and renewed in 2003”). 
 11. Though systems for sharing data among participating researchers 
were used in large-scale scientific projects such as the Manhattan Project and 
the NASA space launches, the release of data to the public was not a priority 
in these projects. 
 12. See, e.g., HGP Initial Paper, supra note 4, at 864 (“[w]e believed that 
scientific progress would be most rapidly advanced by immediate and free 
availability of the human genome sequence. The explosion of scientific work 
based on the publicly available sequence data in both academia and industry 
has confirmed this judgment”). 
 13. By the late 1980s and the beginning of the HGP, there was already 
heated debate in the United States regarding the patentability of genetic 
material. See ROBERT COOK-DEEGAN, THE GENE WARS – SCIENCE, POLITICS, 
AND THE HUMAN GENOME 308–11 (1994); MCELHENY, supra note 1, at 117. 
The increasing trend toward patenting of genetic material alarmed many of 
the leaders of the HGP. See infra note 92 and accompanying text. 
 14. See Kyrpides, supra note 10, at 627–28. 
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complex ethical, legal, and technical issues, have complicated 
the data release landscape and given rise to additional policy 
considerations. Among these have been (4) the protection of 
human subject data that resides in public databases (data 
protection), and (5) the need for scientists generating large data 
sets to publish their data before it is accessed and used by 
others in order to facilitate their own career advancement and 
grant funding (publication priority).15 The emergence and 
recognition of these considerations has led to an evolution of 
genomics data release policies. The bold pronouncements made 
in Bermuda have given way to more nuanced approaches that 
address differences in types of data and the goals of the projects 
themselves, as well as the differing and sometimes divergent 
requirements of data generators and data users. 
Elinor Ostrom and her colleagues pioneered the analysis of 
common resource structures, whether physical or 
informational, using an organizational theory tool known as the 
Institutional Analysis and Development (IAD) framework, 
work that earned her the 2009 Nobel Prize in Economics.16 
More recently, Michael Madison, Brett Frischmann, and 
Katherine Strandburg have undertaken a thorough re-
examination of the IAD framework in relation to commons in 
the “cultural environment,”17 seeking to combine the 
functionalist IAD approach with metaphorical and narrative 
accounts of commons formation.18 In this paper, I engage the 
theoretical framework of Ostrom and Madison, Frischmann, 
and Strandburg and elucidate both the structural and 
                                                          
 15. Among the factors weighing most heavily against rapid data release is 
the loss by data generators of any “head start” that they might otherwise have 
had in preparing papers analyzing the released data. That is, under a rapid 
data release structure, data generators must release their data very shortly 
after it has been produced, giving competing researchers access to the data at 
the same time as the scientists who generated it. See, e.g., Contreras, Data 
Sharing, supra note 5 (observing that data retention strategies give the data 
generator a head start with respect to analyzing the data). See generally infra 
Section III.B.2 (discussing the process of publishing of results and the 
requirements for making the underlying raw data publicly available). 
 16. Press Release, The Royal Swedish Academy of Sciences (Oct. 12, 
2009), available at 
http://nobelprize.org/nobel_prizes/economics/laureates/2009/press.html. 
 17. Cultural Commons, supra note 5, at 659. Madison, Frischmann and 
Strandburg refer to aggregations of shared information as “cultural commons” 
and include within their far-ranging analysis shared resource structures as 
varied as patent pools, open source software, Wikipedia, the Associated Press, 
and jamband fan communities. Id. at 660–63. 
 18. Id. at 671–74, 681–83. 
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narrative elements of the unique developmental history of the 
genome commons. The IAD methodology offers a systematic 
means for examining the characteristics of a commons 
structure: those of the common resource, the “action arena” in 
which stakeholders interact with the commons and the 
resulting patterns of interaction.19 Each of these broad areas is 
subdivided into further analytical components so that the 
common resource, for example, is assessed with respect to its 
bio-physical characteristics, the attributes of the relevant 
community, and its applicable “rules in use.”20 The application 
of the IAD framework analysis results in a deeper 
understanding of the factors that should be considered when 
structuring or evaluating an information commons. 
Consistent with the IAD methodology, I describe in Part 
II.A the characteristics of the genome commons, including both 
genomic data and the databases in which it is housed. In Part 
II.B, I identify and discuss the various stakeholder 
communities involved in the development and use of the 
genome commons and their predisposition toward the five 
principal policy considerations noted above. In Part III, I trace 
the development of genomic data release policies in the United 
States, beginning with the HGP and the Bermuda Principles 
and concluding with current and planned policies both in 
government-funded and private projects. In Part IV, I analyze 
the impact of the five policy considerations identified above on 
the evolving genome commons landscape, particularly in view 
of the requirements and objectives of the relevant stakeholder 
communities. I conclude with a number of observations 
regarding the applicability of these findings to the design of 
commons in the sciences, generally, and to the future direction 
of the genome commons. 
                                                          
 19. See Elinor Ostrom & Charlotte Hess, A Framework for Analyzing the 
Knowledge Commons, in UNDERSTANDING KNOWLEDGE AS A COMMONS: FROM 
THEORY TO PRACTICE 41, 44–45 (Charlotte Hess & Elinor Ostrom eds., 2006). 
 20. Id. at 45–53. 
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II. ATTRIBUTES OF THE GENOME COMMONS 
A. GENES AND GENOMES 
1. Building Blocks21 
Deoxyribonucleic acid (DNA) is a chemical substance that 
exists in almost every living organism. Each DNA molecule is 
composed of four basic building blocks or nucleotides: adenine 
(A), thymine (T), guanine (G) and cytosine (C). These 
nucleotides form long strings of linked pairs (A-T and G-C) that 
are twisted in a ladder-like chain: the famous “double-helix” 
first described by James Watson and Francis Crick in 1953. 
Each rung of this ladder is referred to as a “base pair”, and the 
full complement of DNA found within an organism is its 
“genome”. The genome of simple organisms such as the E. coli 
bacterium contains approximately five million base pairs, that 
of the fruit fly Drosophila melanogaster contains approximately 
160 million base pairs, and that of Homo sapiens contains 
approximately 3.2 billion base pairs. 
The double-helical strands of DNA that exist within an 
organism’s cells are typically bound into discrete units called 
“chromosomes” (each human carries twenty-three pairs of 
chromosomes). The DNA on each chromosome is divided into 
smaller “genes,” ranging in size from as few as one hundred to 
more than two million base pairs. It is currently estimated that 
humans each possess approximately 25,000 genes, which are 
generally regarded as the basic functional units of DNA. An 
organism’s genes serve many functions. They are responsible 
for the inheritance of traits from one generation to the next, 
and they encode the many proteins responsible for the 
biochemical functions within the cell. Each human genome is 
approximately 99.5 percent identical, but very small differences 
are responsible for the great variability in human physical and 
physiological traits. The observable characteristics of an 
individual, including physical, physiological, behavioral, and 
demographic characteristics, are referred to as that individual’s 
“phenotype.” One of the principal goals of genetic science has 
                                                          
 21. This Section contains a basic explanation of the scientific terminology 
and concepts used throughout this paper. Most of this information can be 
found in any modern biology textbook. In some cases, I have simplified the 
discussion of complex scientific concepts for the general reader. See generally 
LESK, supra note 1; MATTHEW RIDLEY, GENOME 6–10 (1999); WILLIAM S. 
KLUG & MICHAEL R. CUMMINGS, ESSENTIALS OF GENETICS (3d ed. 1999). 
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been to associate particular genes, genetic variations, or 
“mutations” with phenotypic traits. 
2. Medical Genetics 
As early as 1902, scientists began to associate hereditary 
diseases with genes passed down from parents to their 
offspring. But while numerous conditions were associated with 
patterns of inheritance, from relatively benign traits such as 
albinism and hair color to debilitating ailments such as cystic 
fibrosis, Down syndrome, and Huntington’s disease, it was not 
until the 1970s that technology had advanced to a state 
sufficient to enable scientists to identify the individual genes 
responsible for these conditions. Even then, each of these 
discoveries took years of painstaking work and a measure of 
good luck to achieve. It was not until 1986 that a revolutionary 
new process for copying DNA fragments called polymerase 
chain reaction (PCR) enabled the large-scale, rapid sequencing 
of DNA. The advent of PCR technology soon gave rise to 
ambitious plans to sequence not only genes identified with 
specific diseases, but the entire human genome. 
3. The Human Genome Project22 
The Human Genome Project was formally launched in 
1990 as a joint project of the National Institutes of Health 
(NIH)23 and the U.S. Department of Energy (DOE),24 with 
                                                          
 22. The Human Genome Project, and particularly the race between the 
publicly-funded HGP and Celera Genomics, has been the subject of numerous 
popular and scholarly accounts. See generally SHREEVE, supra note 9; J. CRAIG 
VENTER, A LIFE DECODED: MY GENOME, MY LIFE (2007); NRC – GENOMIC AND 
PROTEOMIC RESEARCH, supra note 6, at 34–36; INSTITUTE OF MEDICINE & 
NATIONAL RESEARCH COUNCIL, LARGE-SCALE BIOMEDICAL SCIENCE 31–40 
(2003) [hereinafter LARGE-SCALE SCIENCE]; HGP Initial Paper, supra note 4, 
at 862–63. The early days of the HGP are extensively chronicled by Robert 
Cook-Deegan in COOK-DEEGAN, supra note 13. 
 23. The National Institutes of Health (NIH) formed the National Center 
for Human Genome Research (NCHGR) in 1989, under the direction of James 
Watson, to carry out its component of the HGP. In 1997, the Department of 
Health and Human Services elevated NCHGR to the status of a full “institute” 
within the NIH system, forming the National Human Genome Research 
Institute (NHGRI). About NHGRI: A Brief History and Timeline, NATIONAL 
HUMAN GENOME RESEARCH INSTITUTE, http://www.genome.gov/10001763 (last 
visited Oct. 28, 2010). 
 24. DOE’s interest in a genome sequencing project arose from its work on 
genetic mutations among atomic bomb survivors. See COOK-DEEGAN, supra 
note 13, at 93–95. DOE was also the overseer of the GenBank DNA sequence 
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support from the Wellcome Trust in the United Kingdom and 
the involvement of groups in the United Kingdom, France, 
Germany, and Japan.25 In its initial stages, the HGP sought to 
build infrastructure, improve sequencing technologies, and 
sequence the genomes of smaller model organisms. Building on 
success with these early efforts, the international initiative to 
sequence the human genome commenced in 1996 with plans to 
complete the full sequence by 2005.26 
By 1998, the HGP had spent nearly two billion dollars with 
relatively little progress other than the sequences for the model 
organisms.27 Then, in May, J. Craig Venter, a former NIH 
scientist, famously proclaimed that he, funded by substantial 
commercial backers, would utilize a battalion of three-hundred 
state-of-the-art sequencing machines to sequence the entire 
human genome in only three years, a full four years before the 
publicly-funded HGP.28 Venter’s announcement led to a 
technological “arms race” between his new company, Celera 
Genomics, and the HGP, a race in which competing claims and 
accusations became regular features in the scientific literature 
and the popular press.29 Ultimately, a truce was declared, and, 
in June 2000, the leaders of the competing groups made a joint 
White House announcement that a “first draft” of the human 
genome sequence had been completed.30 The draft sequence 
was published in the public GenBank database in 2001.31 
 
                                                          
database at Los Alamos National Laboratory, which it established in 1983. 
LARGE-SCALE SCIENCE, supra note 22, at 31. See generally Stephen 
Hilgartner, Potential Effects of a Diminishing Public Domain in Biomedical 
Research Data, in NATIONAL RESEARCH COUNCIL, THE ROLE OF SCIENTIFIC 
AND TECHNICAL DATA AND INFORMATION IN THE PUBLIC DOMAIN: 
PROCEEDINGS OF A SYMPOSIUM 137 (2003) (describing the history of GenBank 
and its predecessor, the Los Alamos Sequence Library). 
 25. SHREEVE, supra note 9, at 45–47. 
 26. See NRC – GENOMIC AND PROTEOMIC RESEARCH, supra note 6, at 35. 
 27. Nicholas Wade, Scientist’s Plan: Map All DNA Within 3 Years, N.Y. 
TIMES, May 10, 1998, at 20. 
 28. SHREEVE, supra note 9, at 22–23; Leslie Roberts, Controversial from 
the Start, 291 SCIENCE 1182, 1187; Wade, supra note 27, at 1. 
 29. See Roberts, supra note 28, at 1188. 
 30. Roberts, supra note 28, at 1188; Nicholas Wade, Genetic Code of 
Human Life is Cracked by Scientists: A Shared Success, N.Y. TIMES, June 27, 
2000, at A1. 
 31. See HGP Initial Paper, supra note 4. 
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4. The Post-Genome World 
The completion of the human genome sequence has had a 
significant impact on biomedical science.32 The genetic basis for 
thousands of common hereditary diseases is now known, and 
widely-available genetic tests exist for many common diseases 
and other physical traits.33 Related fields such as proteomics 
(the study of protein expression throughout an organism) have 
also benefitted from the technological and scientific advances 
made possible by the HGP.34 Today, additional international 
efforts are under way to sequence the genomes of one thousand 
individual humans to create the most complete and detailed 
reference map of the human genome to-date (the “1000 
Genomes Project”)35 and to sequence the genomes of some of 
the multitude of microorganisms residing within the human 
body (the “Human Microbiome Project”).36 
The public human genome map has also enabled 
researchers to conduct studies to determine complex 
combinations of genetic factors contributing to disease. 
Whereas earlier studies took years to identify single genes 
responsible for specific inherited diseases, recent “genome-wide 
association studies” (GWAS or GWA studies) have been 
credited with identifying variants in multiple genes that 
increase susceptibility for complex conditions such as Type 2 
diabetes,37 breast cancer,38 prostate cancer,39 hypertension,40 
                                                          
 32. See, e.g., COLLINS, supra note 1, at 3 (“[v]irtually all biomedical 
researchers would agree that their approach to understanding how life works 
has been profoundly and irreversibly affected by access to the complete DNA 
sequence of the human genome, and that of many other organisms”). 
 33. As of December 6, 2009, NCBI’s GeneTests web site identified 1830 
different diseases for which genetic tests are available. GENE TESTS, 
http://www.ncbi.nlm.nih.gov/sites/GeneTests/?db=GeneTests (last visited Dec. 
6, 2009). 
 34. See NRC – GENOMIC AND PROTEOMIC RESEARCH, supra note 6, at 38–
40; LESK, supra note 1, at 305–07. 
 35. Erika Check Hayden, International Genome Project Launched, 451 
NATURE 378, 378 (2008). 
 36. Peter J. Turnbaugh et al., The Human Microbiome Project, 449 
NATURE 804, 804 (2007). 
 37. Laura J. Scott et al., A Genome-Wide Association Study of Type 2 
Diabetes in Finns Detects Multiple Susceptibility Variants, 316 SCIENCE 1341 
(2007); Robert Sladek, A Genome-Wide Association Study Identifies Novel Risk 
Loci for Type 2 Diabetes, 445 NATURE 881(2007). 
 38. D.F. Easton et al., Genome-Wide Association Study Identifies Novel 
Breast Cancer Susceptibility Loci, 447 NATURE 1087 (2007); D.J. Hunter et al., 
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and numerous other diseases.41  Such studies, which involve 
scanning the entire human genome for variants that are 
common among persons with similar diseases or other 
observable traits, have been made possible by dramatic 
advances in the technology used to sequence and analyze the 
vast quantities of data embedded within human DNA and 
similarly dramatic reductions in the cost of sequencing 
technology.42 
B. DATA AND DATABASES 
1. Publication of Results 
The peer-reviewed journal article is the traditional means 
of disseminating scientific information.43  Scientists are judged, 
both for purposes of career advancement and the awarding of 
government grants, on the quantity of their publications, 
                                                          
A Genome-Wide Association Study Identifies Alleles in FGFR2 Associated with 
Risk of Sporadic Postmenopausal Breast Cancer, 39 NATURE GENETICS 870 
(2007). 
 39. Meredith Yeager et al., Genome-Wide Association Study of Prostate 
Cancer Identifies a Second Risk Locus at 8q24, 39 NATURE GENETICS 645 
(2007). 
 40. Adebowale Adeyemo et al., A Genome-Wide Association Study of 
Hypertension and Blood Pressure in African Americans, PLOS GENETICS (July 
2009), http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal. 
pgen.1000564. 
 41. See, e.g., The Wellcome Trust Case Control Consortium, Genome-Wide 
Association Study of 14,000 Cases of Seven Common Diseases and 3,000 
Shared Controls, 447 NATURE 661 (2007); Monya Baker, Genetics by Numbers, 
451 NATURE 516 (2008) (discussing GWA study of several common diseases); 
Lucia A. Hindorff et al., Potential Etiologic and Functional Implications of 
Genome-Wide Association Loci for Human Diseases and Traits, 106 
PROCEEDINGS OF THE NAT. ACAD. SCI. 9362 (2009) (discussing an online 
catalog of GWAS association data that references hundreds of publications 
identifying more than 100 diseases and traits). 
 42. In 1985, the cost of sequencing a single human DNA base pair was 
approximately $10.00.  That cost decreased to $1.00 by 1991, $0.10 by 1993, 
and approximately $0.001 by 2006.  LESK, supra note 1, at 23.  Between 1999 
and 2009, the cost of gene sequencing technology dropped by an astonishing 
factor of 14,000.  Collins, supra note 4, at 674. The NHGRI is currently 
funding the development of technology capable of sequencing an entire human 
genome (approximately 3.2 billion base pairs) for a cost of $1,000. See Collins, 
supra note 4, at 675. 
 43. See ROBERT K. MERTON & HARRIET ZUCKERMAN, INSTITUTIONALIZED 
PATTERNS OF EVALUATION IN SCIENCE (1971), reprinted in THE SOCIOLOGY OF 
SCIENCE 460, 463–65 (Norman W. Storer ed., 1973) (tracing the origin of 
scientific publication to the advent of printing and the establishment of the 
first scientific journals in 1665). 
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making the publication of articles of paramount importance to 
many scientists and giving scientists a significant personal 
incentive to publish and, thus, share their data with others.44  
A significant period of time, however, typically elapses between 
the point at which experimental data are generated and the 
time that they are published. This delay reflects the time 
required for the investigators to analyze their results, gather 
additional data, refine their analysis, prepare a paper based on 
their findings, and submit the paper to journals; for the 
journals to conduct their peer review and editorial process; for 
the investigators to make any revisions required by the 
journals (including, at times, to conduct additional 
experiments) or, if the paper is rejected by the journal, to revise 
and submit it to different journals; and, finally, for the journal 
to edit, format, and prepare the accepted paper for publication. 
One recent study reports that the period from completion of 
scientific work until publication is typically between twelve and 
eighteen months.45  Older studies have found comparable or 
longer delays in other fields of research.46 
 
                                                          
 44. ROBERT K. MERTON, PRIORITIES IN SCIENTIFIC DISCOVERY (1957), 
reprinted in THE SOCIOLOGY OF SCIENCE 286, 316 (Norman W. Store red., 
1979) (noting the “tendency, in many academic institutions, to transform the 
sheer number of publications into a ritualized measure of scientific or 
scholarly accomplishment”); RESEARCH INFO. NETWORK, TO SHARE OR NOT TO 
SHARE: PUBLICATION AND QUALITY ASSURANCE OF RESEARCH DATA OUTPUTS 
25 (2008), available at www.rin.ac.uk/data-publication (the assessment of 
researchers is “perceived to value above all else the publication of papers in 
high-impact journals”). 
 45. Carlos B. Amat, Editorial and Publication Delay of Papers Submitted 
to 14 Selected Food Research Journals.  Influence of Online Posting, 74 
SCIENTOMETRICS 379 (2008). 
 46. See William D. Garvey & Belver C. Griffith, Scientific Information 
Exchange in Psychology, 146 SCIENCE 1655, 1656 (1964) (reporting that in the 
psychology field, their study indicated that the time between hypothesis and 
publication is between 30 and 36 months, and the time between reportable 
results and publication is between 18 and 21 months); Charles G. Roland & 
Richard A. Kirkpatrick, Time Lapse Between Hypothesis and Publication in 
the Medical Sciences, 292 NEW ENG. J. MED. 1273, 1274 (1975) (finding delays 
of 20 and 24 months between the completion of research and publication, 
respectively, for medical laboratory research and clinical research studies).  
Anecdotally, the author has been informed that publication delays are 
typically even longer in the social sciences. 
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2. Raw Data 
Despite the abundant incentives for scientists to share 
data via publication, the data set published in most journal 
articles represents only a small portion of the “raw” data 
collected in a given research project.47  This data set is typically 
presented in a summary fashion and is intended primarily to 
support the scientist’s analysis and conclusions.48  Yet in order 
to enable the verification and reproduction of an experiment by 
other scientists, the full data set is often required. Thus, a 
growing number of scientific journals now require that authors 
make the data underlying their published results available to 
readers as well.49  In the case of genomic sequence data, 
journals often require a deposit of the data at the time of 
publication into a public database,50 such as NIH’s Genbank51 
or dbGaP52. These requirements, coupled with the funding 
agency’s data release requirements described below, have 
enabled the efficient, rapid, and cost-effective sharing of new 
knowledge and the pursuit of studies and analyses that 
                                                          
 47. See generally Rebecca S. Eisenberg, Patents and Data-Sharing in 
Public Science, 15 INDUS. & CORP. CHANGE 1013, 1024 (2006). 
 48. Id. 
 49. See, e.g., Guide to Publication Policies of the Nature Journals, 
NATURE, http://www.nature.com/authors/gta.pdf (last updated Apr. 30, 2009); 
General Information for Authors, AM. ASS’N FOR THE ADVANCEMENT OF SCI., 
http://www.sciencemag.org/about/authors/prep/gen_info.dtl (last visited Oct. 
27, 2010); Information for Authors, PROCEEDINGS OF THE NAT’L ACAD. OF SCI., 
http://www.pnas.org/site/misc/iforc.shtml#viii (last visited Oct. 27, 2010). 
 50. See Hilgartner, supra note 24, at 137. 
 51. Today, GenBank is administered by the National Center for 
Biotechnology Information (NCBI) and forms one of three international 
nucleotide libraries that work in close partnership, and the others are the 
European Molecular Biology Library (EMBL) in Hinxton, England, and the 
DNA Data Bank of Japan (DDBJ).  See LESK, supra note 1, at 251.  The 
quantity of data in GenBank increased from about 2 billion base pairs in 1999 
to 86 billion in 2008.  Mike May, Sharing the Wealth of Data, SCI. AM. 
WORLDVIEW 88, 89 (2009). 
 52. The Database of Genotypes and Phenotypes (dbGaP) operated by the 
NIH’s National Library of Medicine can accommodate phenotypic data, which 
includes elements such as de-identified subject age, ethnicity, weight, 
demographics, exposure, disease state, and behavioral factors, which is far 
more complex to record, search and correlate than the raw sequence data 
deposited in GenBank, and in addition to genotypic and phenotypic data, 
dbGaP can accommodate study documentation and statistical results, 
including linkage and association analyses.  See generally DBGAP, 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=gap (last visited Oct. 27, 
2010). 
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otherwise might have been impossible.53  As Hess and Ostrom 
observe, modern biology has been transformed into an 
“information science.”54 
C. ACTORS AND STAKEHOLDERS 
Much of the early work regarding common resource 
structures was devoted to understanding the attributes of the 
different communities that shared the commons, whether 
herdsmen grazing cattle on a common pasture or fishermen 
trolling ocean stocks.55  This analysis is equally valuable in the 
context of the information commons, and in designing “rules in 
use,” policy makers must consider the interests of the different 
communities that both use and develop the common resource, 
including which interests may be overlapping, divergent, and, 
sometimes, contradictory.56 The principal stakeholder 
communities relevant to the genome commons, both initially 
and as it has evolved over time, include the following: 
1. Funders 
The HGP, which cost over $2 billion to complete, has been 
called “the largest and most visible large-scale science project 
in biology to date.”57  As such, the U.S. governmental agencies 
that funded the bulk of the massive project, together with their 
counterparts at the Wellcome Trust in the United Kingdom, 
exerted a significant degree of control over both its technical 
and policy dimensions.58  Consistent with the perceived 
importance of the project, NIH appointed “James Watson, 
Nobel laureate and co-discoverer of the [double-]helical 
structure of DNA,” to oversee the newly-formed National 
                                                          
 53. See Eisenberg,  supra note 47, at 1020. 
 54. Charlotte Hess & Elinor Ostrom, A Framework for Analysing the 
Microbiological Commons, 58 INTL. SOC. SCI. J. 335, 335 (2006). 
 55. See, e.g., Cultural Commons, supra note 5. 
 56. Both Ostrom and Hess and Madison, Frischmann and Strandburg 
emphasize the importance of identifying the various constituencies connected 
with a cultural commons.  Ostrom & Hess, supra note 19, at 48–50; Cultural 
Commons, supra note 5, at 690.  See also Contreras, Data Sharing, supra note 
5, at 40–41. 
 57. LARGE-SCALE SCIENCE, supra note 22, at 29. 
 58. The Wellcome Trust in the U.K., at that time the world’s largest 
private medical charity, also contributed substantial funding and support to 
the project, primarily to the work conducted at the Sanger Centre in 
Cambridge, England.  LARGE-SCALE SCIENCE, supra note 22, at 39. 
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Center for Human Genome Research in 1988.59  Other 
scientists involved in the early planning and execution stages 
of the project were also globally prominent and included a 
significant number of Nobel Prize winners.60  This leadership 
by preeminent and respected scientists was critical to the HGP 
and gave the group’s decisions a gravitas that they otherwise 
might have lacked. It also engendered among the project’s 
leadership a sense of public stewardship that contributed to the 
public-spirited nature of several HGP policies.61 
2. Data Generators 
Prior to the HGP, genetic research was conducted in 
hundreds of academic laboratories across the world and funded 
primarily by small grants directed toward the investigation of 
specific hypotheses.62  The HGP, by contrast, treated the 
mapping of the human genome as a campaign of large-scale 
data production.63 The NIH funded three major genome centers 
(Baylor College of Medicine, Washington University, and the 
Whitehead Institute) that worked closely with the DOE’s Joint 
Genome Institute and the Sanger Centre in Cambridge, 
England (funded by the Wellcome Trust).64  These five centers 
produced the majority of the data that resulted from the 
                                                          
 59. Id. at 35.  When Watson resigned in 1992 following a dispute over the 
NIH’s attempts to patent small DNA fragments known as expressed sequence 
tags (ESTs), Francis Collins, another high-profile scientist, was appointed to 
replace him.  Id. at 36–37. 
 60. In addition to Watson (Chemistry, 1962), the HGP leadership group 
included Fred Sanger (Chemistry, 1958 and 1980), Hamilton Smith (Medicine, 
1978) and Walter Gilbert (Chemistry, 1980).  Other scientists involved in the 
HGP won the Nobel Prize after the commencement of the project (e.g., John 
Sulston (Medicine, 2002)). See generally Robert Mullan Cook-Deegan, Origins 
of the Human Genome Project, 5 RISK 97 (1994). 
 61. For instance, in 1988, James Watson allocated 3% of the HGP budget 
to investigate the ethical and social implications of sequencing the human 
genome, creating the Ethical, Legal and Social Implications (ELSI) group 
within the HGP, and the budget for ELSI was later raised to 5% of the HGP 
budget, indicating the importance HGP leadership placed on the social impact 
of the HGP. See James D. Watson, Genes and Politics, 75 J. MOLECULAR MED. 
624, 633-34 (1997); Eric T. Juengst, Self-Critical Federal Science? The Ethics 
Experiment Within the U.S. Human Genome Project, 13 SOC. PHIL. & POL’Y 63, 
63 (1996);  see also Peter Lee, Toward a Distributive Commons in Patent Law, 
2009 WIS. L. REV. 917, 950-67 (2009) (analyzing the distributive justice 
interests of public institutions which fund scientific research). 
 62. See Roberts, supra note 28, at 1185. 
 63. Id. at 1182. 
 64. See LARGE-SCALE SCIENCE, supra note 22, at 39. 
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HGP.65 The intensity of this work, the amount of capital 
equipment required to undertake it, and the degree of 
specialization required by the new science of genomics led to 
the creation of a new breed of scientist: one whose principal 
research aim was the generation of large data sets rather than 
the development and testing of hypotheses. This distinction 
persists today as the number of data-generating projects in the 
biosciences continues to increase.66  The factors motivating 
these data-generating scientists are twofold: (1) obtaining 
continued grant funding for their work and (2) advancing their 
careers through publication and peer recognition. But while 
governmental funding of new data generation projects 
continues, data generating scientists face challenges when it 
comes to publishing their work in traditional scientific 
journals.67 
3. Data Users 
Prior to the completion of the HGP, researchers studying a 
particular genetic disease devoted substantial time and effort 
to isolating and sequencing the relevant gene—work that 
would often take years of painstaking trial-and-error 
experimentation.68  The data generated by the HGP and its 
follow-up projects have eliminated the need for researchers to 
conduct much of this groundwork.69 Unlike the close-knit 
community of data generators at large-scale sequencing 
centers, there is no coherent community of data users. These 
users comprise all scientists across the world whose research 
may benefit from the use of genomic data. 
 
 
                                                          
 65. Id. 
 66. The implications of participating in large-scale data generating work 
on the careers of junior scientists have been the subject of much discussion.  
See LARGE-SCALE SCIENCE, supra note 22, at 26–27; Kaye et al., supra note 
10, at 332–33; Toronto Int’l Data Release Workshop Authors, Pre-Publication 
Data Sharing, 461 NATURE 168, 169–70 (2009) [hereinafter Toronto Report]. 
 67. See Contreras, Prepublication Data Release, supra note 5, at 393; 
Contreras, Data Sharing, supra note 5, at 38. 
 68. See SHREEVE, supra note 9, at 40. 
 69. Id. 
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4. Data Intermediaries 
Individual scientists and laboratories that generate data 
are seldom the ones that make such data available to others, 
except in limited one-on-one interactions with colleagues. In 
most cases, scientists rely on data intermediaries, whether 
scientific journals that publish their analyses and results or 
centralized database managers that host large quantities of 
raw data. Data intermediaries may operate either as 
commercial entities (as in the case of commercial publishers 
and paid database services) or non-profit/governmental entities 
(such as the GenBank and dbGaP databases and “open access” 
journals such as those published by the Public Library of 
Science (PLoS)70). Not surprisingly, the interests of commercial 
and non-commercial data intermediaries differ in several 
regards, most notably in the area of pricing for access to 
information. Nevertheless, these stakeholders also share a 
number of common traits, including the desire to disseminate 
information in ways that are effective, secure, and accurate and 
the need to maintain some level of financial stability.71 
5. Data Subjects 
Human genomic information, by definition, is derived from 
human subjects. Because the goal of the HGP was to generate a 
baseline map of the human genome without regard to the 
particular physiological and pathological traits associated with 
genetic variation among individuals, the genomic sequence 
data generated by the HGP was anonymous and retained no 
association with the individual subjects whose DNA was 
sequenced.72  Similar characteristics applied to other early 
                                                          
 70. See Contreras, Data Sharing, supra note 5, at 38. 
 71. Subscription costs of scientific journals, particularly those of 
commercial publishers, have risen sharply in recent years, and the scientific 
publishing industry often complains of thinning margins and rising expenses, 
issues not unique to the commercial sector while some publicly-funded 
databases also suffer from funding shortfalls and are in danger of 
discontinuation.  See, e.g., Joan B. Schlimgen et al., Update on Inflation of 
Journal Prices: Brandon/Hill List Journals and the Scientific, Technical, and 
Medical Publishing Market, 92 J. MED. LIBR. ASS’N 307 (2004) (analyzing the 
rising costs of scientific journals and the pressures causing that rise); 
Editorial, Access Denied?, 462 NATURE 252 (2009) (describing the threatened 
demise of the NSF-funded TAIR arabidopsis plant genome database). 
 72. The Human Genome Project Completion: Frequently Asked Questions, 
NAT’L HUMAN GENOME RESEARCH INST., http://www.genome.gov/11006943 
(last visited Oct. 28, 2010). 
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genomic projects such as the HapMap Project.73 These data 
were intended to elucidate non-individualized information 
applicable to the human genome in general. In later projects, 
however, and particularly with the commencement of large-
scale GWA studies, concerns with the potential identification of 
human subjects grew because the genotypic data generated by 
a GWA study is not meaningful without the associated 
phenotypic data.74 That is, because a GWA study often seeks to 
associate genotypic information (e.g., genetic markers) with 
particular disease states, information regarding donor 
demographics, disease state, and treatment are necessary to 
interpret the genotypic findings. The prospect of releasing 
clinical and phenotypic data to the public sparked substantial 
concern and has led to the recognition of human data subjects 
as important stakeholders in the genomic data equation.75  
Public concern has only been heightened by the publication in 
2008 of a paper suggesting that the presence of an identifiable 
individual’s DNA can be inferred from a group of samples using 
statistical techniques.76  Such findings suggest that the 
interests of data subjects may require substantial attention as 
genomic science advances and have led to numerous proposals 
for heightened protection of individual identity in publicly-
released genomic data.77 
                                                          
 73. See Eisenberg, supra note 47, at 1026. 
 74. See Toronto Report, supra note 66, at 170. 
 75. For a general discussion of the protection of human subjects data in 
genomic studies, a topic that is beyond the scope of this paper, but which has 
been extensively addressed in the literature. See, e.g., LORI B. ANDREWS, 
MAXWELL J. MEHLMAN & MARK A. ROTHSTEIN, GENETICS: ETHICS, LAW AND 
POLICY 592–630 (1st ed. 2002); Domenic A. Crolla, Reflections on the Legal, 
Social, and Ethical Implications of Pharmacogenomic Research, 46 
JURIMETRICS 239, 241–47 (2006); John A. Robertson, Privacy Issues in Second 
Stage Genomics, 40 JURIMETRICS 59 (1999). 
 76. Nils Homer et al., Resolving Individuals Contributing Trace Amounts 
of DNA to Highly Complex Mixtures Using High-Density SNP Genotyping 
Microarrays, PLOS GENETICS (Aug. 2008), 
http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1
000167. 
 77. See, e.g., P3G Consortium et al., Public Access to Genome-Wide Data: 
Five Views on Balancing Research with Privacy and Protection, PLOS 
GENETICS (Oct. 2009), 
http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1
000665. 
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6. The Public 
The general public cannot be ignored as a key stakeholder 
with respect to genomic research. The HGP generated 
significant public interest and was regularly covered by the 
popular news media.78  Beyond general interest, however, are 
two significant aspects of public engagement with genomics.  
First, government-sponsored research is largely taxpayer-
funded, meaning that public taxpayers and their 
representatives in Congress have a legitimate and significant 
interest in the direction and results of research.79  Second, 
members of the public who are themselves affected, directly or 
indirectly, by genetic disorders or diseases often form patient 
advocacy and disease interest groups.  These groups frequently 
possess a high degree of familiarity with the relevant scientific 
literature and have both the motivation and the financial 
means to lobby for changes in research policy.80 
III. THE EVOLUTION OF RAPID, PRE-PUBLICATION DATA 
RELEASE IN THE GENOME SCIENCES 
A. EARLY YEARS OF THE HGP 
Since the initiation of the HGP, several factors contributed 
to the call to release the data generated by the project to the 
public. First, the early work of the HGP involved sequencing 
the genomes of simple model organisms including the 
roundworm (C. elegans) and mouse (Mus musculus). The 
                                                          
 78. See, e.g., Nicholas Wade, Genome’s Riddle: Few Genes, Much 
Complexity, N.Y. TIMES, Feb. 13, 2001, at F1, available at 
http://www.nytimes.com/2001/02/13/health/13HUMA.html; Justin Gillis, 
Scientists Speed Up Timetable for Mapping Human Genes, WASH. POST, Sept. 
15, 1998, at A2; Leon Jaroff et al., Science: The Gene Hunt, TIME, Mar. 20, 
1989, at 62, available at 
http://www.time.com/time/magazine/article/0,9171,957263,00.html. 
 79. See, e.g., Jonathan Karl et al., Stimulus Slammed: Republican 
Senators Release Report Alleging Waste, ABC NEWS, August 3, 2010, available 
at http://abcnews.go.com/GMA/stimulus-slammed-republican-senators-release-
report-alleging-waste/story?id=11309090 (detailing public and Congressional 
criticism of research on topics such as cocaine use in monkeys, collection of 
exotic ants and the use of yoga among cancer survivors). 
 80. See Lee, supra note 61, at 986–90 (addressing the interests and policy 
concerns of disease advocacy groups); and see e.g., Sharon F. Terry et al., 
Advocacy Groups as Research Organizations: The PXE International Example, 
8 NATURE REVIEWS GENETICS 157, 157–162 (2007) (describing the experience 
of an advocacy organization for the disease pseudoxanthoma elasticum and 
the methods the group used to advance a scientific agenda). 
121_CONTRERAS.DOCX (DO NOT DELETE) 4/4/2011  8:14 AM 
82 MINN. J. L. SCI. & TECH. [Vol. 12:1 
 
 
groups that worked on these organisms abided by strong “open 
science” norms and were accustomed to sharing their data 
freely with one another, laying a strong precedent for the 
HGP.81 Moreover, and perhaps more importantly, there was a 
sense among the leadership of the project, in the words of Ari 
Patrinos, the DOE’s Associate Director for Biological and 
Environmental Research, that “the genome belongs to 
everybody.”82 Accordingly, in 1988 the National Research 
Council recommended that all data generated by the HGP “be 
provided in an accessible form to the general research 
community worldwide.”83 
In 1992, shortly after the project was launched, NIH and 
DOE developed formal guidelines for the sharing of HGP 
data.84 These guidelines were viewed as essential to achieve the 
program’s goals, avoid unnecessary duplication of effort, and 
expedite research in other areas.85 In other words, the putative 
purpose of these guidelines was to facilitate the 
straightforward policy goal of project coordination. The 
guidelines required that data generated by the HGP be 
deposited in public databases (e.g., GenBank), making it 
available to all scientists worldwide.86 But the need for project 
coordination did not require immediate public release of the 
                                                          
 81. See HGP Initial Paper, supra note 4, at 864; MCELHENY, supra note 1, 
at xi (“Openness was at the core of the [bacteriophage] ethos, and it soon 
propagated to the genetic research systems of the future.”); Hilgartner, supra 
note 24, at 89 (“There were . . . communities doing molecular biology . . . on 
yeast and Drosophila that had “open science” norms.  Those norms were the 
ones adopted as the models for the Human Genome Project.”). The evolution of 
the open science culture among C. elegans researchers is described in some 
detail in NRC - GENOMIC AND PROTEOMIC RESEARCH, supra note 6, at 54–56. 
 82. Eliot Marshall, Bermuda Rules: Community Spirit, With Teeth, 291 
SCIENCE 1192 (2001). James Watson, then-director of the National Center for 
Human Genome Research, wrote in 1990 that “making the sequences widely 
available as rapidly as practical is the only way to ensure that their full value 
will be realized and is the only acceptable way to handle information produced 
at public expense.” Watson, supra note 1, at 48. 
 83. NAT’L RESEARCH COUNCIL, MAPPING AND SEQUENCING THE HUMAN 
GENOME 8 (1988) [hereinafter NRC – HUMAN GENOME] (arguing that the 
project’s mapping and sequencing data will be “of little value” if not made 
accessible to the general research community). 
 84. NIH, DOE Guidelines Encourage Sharing of Data, Resources, HUMAN 
GENOME NEWS (Oak Ridge Nat’l Laboratory, Oak Ridge, Ten.), Jan. 1993, at 4 
[hereinafter NIH/DOE Guidelines]. 
 85. Id. 
 86. Id. 
121_CONTRERAS.DOCX (DO NOT DELETE) 4/4/2011  8:14 AM 
2011] BERMUDA’S LEGACY 83 
HGP data. The HGP policy makers in 1992 recognized the need 
to provide data generators with “some scientific advantage from 
the effort they have invested” in generating the data.87 This 
“advantage” manifested itself in a six-month maximum period 
from the time that HGP data are generated until the time that 
they must be made publicly available. During this six-month 
period, HGP researchers could analyze their data and prepare 
publications. Only after the end of the six-month period were 
they required to release the data to the public.88 
The 1992 guidelines, in sharp contrast with later policies, 
also indicate that the agencies would not disfavor investigators 
that wished to secure patent rights in HGP-funded 
discoveries.89 This patent-friendly attitude manifested itself in 
NIH’s nearly disastrous attempt to seek patents on short 
genetic sequences known as expressed sequence tags (ESTs). 
This effort began in 1991, when NIH filed patent applications 
claiming 337 ESTs identified, ironically, by Craig Venter’s 
research group. NIH announced this filing as well as its 
intention to continue to file EST patent applications on a 
monthly basis.90 The public response to this announcement was 
vociferous and triggered what Robert Cook-Deegan describes as 
“an international firestorm.”91 The debate within NIH was 
equally vehement and ultimately led to James Watson’s 
resignation from the agency that oversaw the HGP.92 The EST 
debacle marked a turning point in NIH’s attitude toward 
patents on genetic material. By 1994, a significantly cowed 
NIH elected not to appeal the Patent and Trademark Office’s 
                                                          
 87. Id. 
 88. Id. 
 89. Id. (“[I]ntellectual property protection may be needed for some of the 
data and materials.”). 
 90. See Thomas Barry, Revisiting Brenner: A Proposed Resolution to the 
Debate Over the Patentability of Expressed Sequence Tags Using the Concept of 
Utility Control, 35 AIPLA Q.J. 1, 11 (2007). 
 91. See COOK-DEEGAN, supra note 13, at 330–31 (detailing international 
responses to NIH’s EST patent applications including UK threats to file 
countervailing patent applications, UK and French efforts to forge an 
international anti-patenting agreement, public commitments by Japanese 
investigators not to pursue patents and pronouncements from various 
international scientific conferences). 
 92. Watson decried the EST patenting plan as “sheer lunacy.” SHREEVE, 
supra note 9, at 84–85. The NIH’s and DOE’s own advisory committees were 
“unanimous in deploring the decision to seek such patents.” COOK-DEEGAN, 
supra note 13, at 317. 
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rejection of its initial EST patent applications,93 and, since 
then, it has adopted a consistently lukewarm, if not outright 
averse, attitude toward the patenting of genetic sequences.94 
This attitude is reflected in NIH’s support for the Bermuda 
Principles and in the data release and patent policies adopted 
by NIH in the years thereafter. 
B. THE BERMUDA PRINCIPLES 
1. The Birth of Rapid Pre-Publication Data Release 
The year 1996 marked a turning point for the HGP. Not 
only was it the year in which sequencing of the human genome 
was scheduled to begin, it also signaled a sea change in the 
data release landscape. That February, approximately fifty 
scientists and policy-makers met in Hamilton, Bermuda95 to 
deliberate over the speed with which HGP data should be 
released to the public and whether the six-month “holding 
period” approved in 1992 should continue.96 The resulting 
Bermuda Principles established that all DNA sequence 
information from large-scale human genomic sequencing 
                                                          
 93. See LARGE-SCALE SCIENCE, supra note 22, at 36–37. The patentability 
of ESTs has subsequently been addressed by the U.S. Court of Appeals for the 
Federal Circuit in In re Fisher, 421 F.3d 1365, 1374 (Fed. Cir. 2005) (holding 
that the claimed ESTs do not meet the utility requirement of 35 U.S.C. § 101 
because they do not identify the function for the underlying protein-encoding 
genes). 
 94. In 1999, based partially on its experience with the EST patent 
applications, NIH formally urged the PTO to impose stricter utility standards 
when considering DNA-based patents. See NRC - GENOMIC AND PROTEOMIC 
RESEARCH, supra note 6, at 53. For an overview of legal objections to the 
practice of patenting ESTs, see id. at 52, and Barry, supra note 90, at 18–21. 
 95. The International Strategy Meeting on Human Genome Sequencing 
meeting was sponsored by the Wellcome Trust and included representatives of 
NIH and DOE, the Wellcome Trust, UK Medical Research Council, the 
German Human Genome Programme, the European Commission, the Human 
Genome Organisation (HUGO) and the Human Genome Projects of France 
and Japan. In addition to the data release issues addressed in this paper, and 
for which the meeting is best known, attendees also discussed and debated 
issues relating to sequencing strategies, software tools and informatics 
methodologies. See International Large-Scale Sequencing Meeting, HUMAN 
GENOME NEWS (Oak Ridge Nat’l Laboratory, Oak Ridge, Ten.), Apr.–June 
1996, at 19. 
 96. See Marshall, supra note 82, at 1192; Robert Cook-Deegan & Stephen 
J. McCormack, A Brief Summary of Some Policies to Encourage Open Access to 
DNA Sequence Data, 293 SCIENCE 217 supp. (2001), available at 
http://www.sciencemag.org/cgi/content/full/293/5528/217/DC1. 
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projects should be “freely available and in the public domain in 
order to encourage research and development and to maximize 
its benefit to society.”97 They went on to define the method by 
which such data should be shared, requiring that sequence 
assemblies greater than one kilobase (Kb) in length98 should be 
released automatically within twenty-four hours and that 
finished annotated sequences should be submitted immediately 
to a public database.99 
The Bermuda Principles were revolutionary in that they 
established for the first time that data from public genomic 
projects should be released to the public almost immediately 
after their generation. Elimination of the six-month data 
holding period established in 1992 was supported by both the 
NIH and DOE and had significant international 
ramifications.100 Even Craig Venter and Celera Genomics 
eventually agreed to make the data from their competing effort 
to sequence the human genome available to the public.101 
                                                          
 97. Bermuda Principles, supra note 6. 
 98. Id. One kilobase (Kb) represents 1,000 base pairs. The human genome 
consists of approximately 3.2 billion base pairs. One Kb is thus a very small 
increment of the genetic code that corresponds to an initial “read” by gene 
sequencing technology of the 1990s. At a follow-up meeting held in Bermuda 
in 1997, this requirement was changed to apply to sequence assemblies of 2 Kb 
or more in size to ensure that the released sequences include at least two 
sequence reads for greater reliability. 
 99. Id. 
 100. Among other things, the Bermuda Principles contributed to the 
German government’s 1997 decision to revoke its rule granting German 
companies three months privileged access to human genome sequence data 
generated with German government funding. Allison Abbott, Germany Rejects 
Genome Data ‘Isolation’, 387 NATURE 536, 536 (1997). 
 101. Though Celera ultimately made its sequence data publicly-available, 
the path that led to this result was bumpy and circuitous. Unlike the public 
HGP, Celera offered its data on a commercial web site, rather than the public 
GenBank database. Celera allowed scientists from non-profit and academic 
institutions to access it without charge but required that scientists who 
wished to use the data for commercial purposes enter into a license 
agreement. Eliot Marshall, Storm Erupts over Terms for Publishing Celera’s 
Sequence, 290 SCIENCE 2042, 2042 (2000). This approach outraged much of the 
scientific community and led to a highly-publicized debate. Ultimately a 
settlement was brokered by the journal Science, which published Celera’s 
article announcing its draft of the human genome sequence, provided that the 
company make its data broadly available (the competing HGP article was 
published by Nature on the same day). Eliot Marshall, Sharing the Glory, Not 
the Credit, 291 SCIENCE 1189–93 (2001). Celera’s subscription-based data 
business was ultimately unsuccessful and, in 2005, the company finally 
released its human, rat and mouse genomic data to GenBank. Jocelyn Kaiser, 
Celera to End Subscriptions and Give Data to Public GenBank, 308 SCIENCE 
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The Bermuda Principles achieved several of the most 
important policy objectives held by the HGP funders. First, 
they critically enhanced project coordination by enabling the 
HGP sequencing centers to obtain regularly-updated data sets 
from one another to avoid duplication of effort and to optimize 
their respective tasks.102 Waiting six months to obtain data 
under the 1992 policy was simply not practical if the project 
were to function effectively. Second, the funders, particularly 
the prominent leaders chosen to lead the HGP, argued that 
rapid data release was the best way to maximize scientific 
advancement (i.e., putting sequence data into the hands of as 
many laboratories as possible as quickly as possible to 
accelerate the solution of problems for the benefit of society).103 
Finally, rapid data release under the Bermuda Principles 
severely limited the ability of private parties to obtain patent 
protection on data generated by the HGP, thus satisfying the 
policy goal of minimizing encumbrances that was deeply held 
by several HGP leaders.104 In particular, the Bermuda 
Principles ensured that HGP data would be made publicly-
available before data generators could file patent applications 
covering “inventions” arising from that data and in a manner 
that ensured its availability as prior art against third-party 
patent filings at the earliest possible date.105 This result, 
                                                          
775, 775 (2005). 
 102. David R. Bentley, Genomic Sequence Information Should be Released 
Immediately and Freely in the Public Domain, 274 SCIENCE 533, 533 (1996); 
see also Adam Bostanci, Sequencing Human Genomes, in FROM MOLECULAR 
GENETICS TO GENOMICS 174 (Jean-Paul Gaudilliére & Hans-Jörg Rheinberger 
eds., 2004) (arguing that the immediate publication requirement was 
successful in reducing the risk of duplication posed by researchers’ tendency to 
focus on lucrative genes). 
 103. See Bentley, supra note 102, at 533 (insisting that, because sequences 
derive their value from effective interpretation and use, the public good 
requires that raw sequences be made available to the greatest number of 
scientists as quickly as possible); Cook-Deegan & McCormack, supra note 96 
(“[W]ithout [the Bermuda Principles], the wait for information sufficient to 
meet patent criteria from high throughput sequencing programs would lead to 
long delays, and thus be a serious drag on science, undermining the publicly 
funded sequencing programs’ very purpose.”). 
 104. Bentley, supra note 102, at 533-34; see also Marshall, supra note 82; 
JAMES D. WATSON ET AL., RECOMBINANT DNA 295 (3d ed. 2005). 
 105. In jurisdictions such as the European Union and Japan that have so-
called “absolute novelty” requirements, an invention may not be patented if it 
has been publicly disclosed prior to the filing of a patent application. See JOHN 
GLADSTONE MILLS III ET AL., PATENT LAW FUNDAMENTALS §2:30 (perm. ed., 
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though praised by many, was also criticized by those who 
believed that the NIH’s adoption of this anti-patenting 
approach contravened the requirements of the Bayh-Dole Act of 
1980, which expressly favors the patenting of federally-funded 
inventions for the benefit of the U.S. economy.106 
In response to this criticism, the National Human Genome 
Research Institute’s (NHGRI) 1996 policy adopting the 
Bermuda Principles explicitly acknowledges the Bayh-Dole Act, 
noting that recipients of NIH funding have the right to choose 
to apply for patents on inventions that “reveal convincing 
evidence for utility,” but it goes on to warn that “NHGRI will 
monitor grantee activity in this area to learn whether or not 
attempts are being made to patent large blocks of primary 
human genomic DNA sequence.”107 The consequences if such 
                                                          
rev. vol. May 2009). In such countries, a description of the invention in a 
scientific journal could preclude the inventor from obtaining patent protection 
for his or her invention. In the United States, a patent application may be filed 
with respect to an invention that has been disclosed in a printed publication, 
but only if the publication occurred less than one year before the filing of the 
patent application. 35 U.S.C. § 102(b) (2006). Thus, if an inventor wishes to 
seek patent protection for his or her invention, he or she must file a patent 
application prior to the disclosure of the invention in a publication (or, in the 
United States, no more than one year following publication). See Eisenberg, 
supra note 47, at 1025–26 (discussing the creation of “patent-defeating” prior 
art through the HGP’s data release rules). 
 106. Bayh-Dole Act of 1980, 35 U.S.C. §§ 200-12 (2006) (“It is the policy and 
objective of the Congress to use the patent system to promote the utilization of 
inventions arising from federally supported research or development.”). The 
Act rationalized the previously chaotic rules governing federally-sponsored 
inventions and allowed researchers to obtain patents on inventions arising 
from government-funded research. Penalties, including forfeiture of rights, 
could result from an institution’s failure to pursue patent protection for a 
federally-funded invention. 35 U.S.C. § 202(c)(3). Commentators have argued 
that NIH’s adoption of the rapid data release requirements of Bayh-Dole 
deliberately thwart patent protection on genomic inventions. See Arti K. Rai & 
Rebecca S. Eisenberg, Bayh-Dole Reform and the Progress of Biomedicine, 66 
LAW & CONTEMP. PROBS. 289, 308 (2003) (“Arguably, NIH has acted outside 
the scope of its statutory authority . . . at least with respect to patentable 
inventions.”); SHREEVE, supra note 9, at 46 (“Strictly speaking, the policy 
directly contradicted the Bayh-Dole Act.”). 
 107. NATIONAL HUMAN GENOME RESEARCH INSTITUTE, NHGRI POLICY 
REGARDING INTELLECTUAL PROPERTY OF HUMAN GENOMIC SEQUENCE (April 
9, 1996) [hereinafter NHGRI 1996 POLICY], available at 
http://www.genome.gov/10000926. In a 1999 NIH-wide policy applicable to all 
biomedical research tools, the agency expressly stated that the goals of the 
Bayh-Dole Act can be met through publication or databank deposit of 
generally-applicable research tools, and that restrictive licensing of such 
inventions would be “antithetical” to the goals of the Act. Principles and 
Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining 
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patenting activity is discovered are left unstated, but the clear 
implication is that the agency may view future grant 
applications by “violators” unfavorably.108 
The significance of NHGRI’s implementation of the 
Bermuda Principles109 cannot be overstated. Prior to 1996, 
NHGRI’s position with respect to data release and intellectual 
property was not very different than that of other federal 
agencies.110 But in the negotiations at and leading up to the 
Bermuda meeting, the scientific community’s acknowledgement 
of the collective norms of data sharing and the public domain, 
bolstered by the gravitas of several Nobel laureates and other 
leading figures, seems to have captured the agency’s 
imagination. These norms have since become ingrained as part 
of NHGRI’s basic position treating genomic data as a public 
good that should be widely available and unencumbered. 
2. Data Generators versus Data Users 
In their effort to promote the policy goals of project 
coordination, scientific advancement, and minimizing 
encumbrances, the HGP organizers sacrificed the interests of 
data generators. That is, the rapid data release requirements of 
the Bermuda Principles effectively eliminated the ability of 
                                                          
and Disseminating Biomedical Research Resources: Final Notice, 64 Fed. Reg. 
72,090, 72,093 (Dec. 23, 1999). 
 108. For a general critique of the NIH’s “hortatory” approach to this issue, 
see Rai & Eisenberg, supra note 106, at 293-94, 306. Interestingly, the 
National Cancer Institute (NCI) followed a different approach when 
addressing concerns over the release of genomic data and the requirements of 
the Bayh-Dole Act with its Cancer Genome Anatomy Program (CGAP) in 
2000. Rather than issuing policy statements along the lines of NHGRI, NCI 
invoked a seldom-used provision of the Bayh-Dole Act seeking a declaration of 
“exceptional circumstances” to retain the intellectual property rights in cDNA 
sequences generated by CGAP’s contractors. See NCI FREDERICK CANCER 
RESEARCH AND DEVELOPMENT CENTER, MOLECULAR TARGET LIBRARIES 
(MTLS), reprinted in COM. BUD. DAILY, Feb. 24, 2000. Because NCI did not 
pursue patent protection for the sequences, they were effectively contributed 
to the public domain. The procedures relating to such declarations of 
“exceptional circumstances” are involved and time-consuming and, because 
they have not been widely utilized, unpredictable. See Rai & Eisenberg, supra 
note 106. 
 109. See NHGRI 1996 POLICY, supra note 107; NATIONAL HUMAN GENOME 
RESEARCH INSTITUTE, CURRENT NHGRI POLICY FOR RELEASE AND DATABASE 
DEPOSITION OF SEQUENCE DATA (Mar. 7, 1997) [hereinafter NHGRI 1997 
POLICY], available at http://www.genome.gov/page.cfm?pageID=10000910. 
 110. See discussion of NASA and other federal policies supra note 8. 
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data generators to publish analyses and conclusions based on 
their data before others could access it via public means.111 The 
implications of this effect were not realized immediately, but, in 
the years immediately following the completion of the HGP, a 
number of large-scale, publicly-funded genomics projects 
adopted data release policies that reflect an increasing 
recognition of the inherent tension between data generators 
and data users. This distinction was first codified in a new 
NHGRI data release policy adopted shortly after the Third 
International Strategy Meeting on Human Genome Sequencing 
held at Cold Spring Harbor in May 2000.112 The NHGRI 2000 
policy reaffirmed the Institute’s 1997 Bermuda-based 
requirement that initial genomic sequence assemblies be 
deposited into GenBank within twenty-four hours of assembly 
and extended the earlier policy to later-stage data.  For the first 
time, however, it also imposed formal requirements on users 
who accessed and downloaded the released data.  The policy 
acknowledges “the widely accepted ethic in the scientific 
community that those who generate the primary data freely 
should have both the right and responsibility to publish the 
work in a peer-reviewed journal.”113  Thus, the policy expressly 
prohibits users from employing the public data “for the initial 
publication of the complete genome sequence assembly or other 
large-scale analyses,”114 thereby reserving this right to the data 
generators.  Moreover, when data users do utilize the publicly-
available sequence data, they are required to acknowledge its 
source. 
                                                          
 111. Deanna M. Church & LeDeana W. Hillier, Back to Bermuda: How is 
Science Best Served? 10 GENOME BIOLOGY 105, 105.1 (Apr. 24, 2009) (“[T]here 
was some concern that [the policy] would jeopardize the genome center’s 
ability to analyze and publish the data they had produced.”). 
 112. See NATIONAL HUMAN GENOME RESEARCH INSTITUTE, NHGRI POLICY 
FOR RELEASE AND DATABASE DEPOSITION OF SEQUENCE DATA (Dec. 21, 2000) 
[hereinafter NHGRI 2000 POLICY], available at 
www.genome.gov/page.cfm?pageID=10000910. 
 113. Id. 
 114. Id.  While this prohibition represents an important gain for data 
generators, it does not address their more fundamental concern with the 
publication of analyses based on the data they have generated, as opposed to 
the raw data itself. 
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C. FT. LAUDERDALE AND COMMUNITY RESOURCE PROJECTS 
(CRPS) 
1. Reaffirmation of Bermuda 
Questions regarding the ongoing validity of the Bermuda 
Principles began to emerge following the completion of the 
HGP. In order to address these concerns, the Wellcome Trust 
sponsored a 2003 meeting in Ft. Lauderdale, Florida to revisit 
rapid data release issues in the “post-genome” world. The 
meeting was attended by representatives of funding agencies, 
sequencing centers, database managers, biological laboratories, 
and scientific journals, many of whom were involved in the 
original HGP.115 The Ft. Lauderdale participants 
“enthusiastically reaffirmed” the 1996 Bermuda Principles.116 
The most significant outcome of the Ft. Lauderdale meeting 
was a consensus that the Bermuda Principles should apply to 
each “community resource project” (CRP), meaning “a research 
project specifically devised and implemented to create a set of 
data, reagents or other material whose primary utility will be 
as a resource for the broad scientific community.”117 
Under this definition, the twenty-four hour rapid release 
rules of Bermuda would be applicable to large-scale projects 
generating non-human sequence data (e.g., the Mouse Genome 
Consortium), other basic genomic data maps (e.g., the SNP 
Consortium and International HapMap Consortium), and other 
collections of complex biological data, such as protein 
structures and gene expression information.118 In order to 
effectuate this data release requirement, funding agencies were 
urged to designate appropriate efforts as CRPs and to require, 
as a condition of funding, that rapid pre-publication data 
release be required in such projects.119 
                                                          
 115. Report of Meeting organized by the Wellcome Trust, Sharing Data 
from Large-Scale Biological Research Projects: A System of Tripartite 
Responsibility (Jan. 14–15, 2003), [hereinafter Ft. Lauderdale Principles], 
available at http://www.genome.gov/Pages/Research/WellcomeReport0303.pdf. 
 116. Id. at 2 (recognizing, in addition, that considerations might apply to 
data other than large-scale genomic sequences). 
 117. Id. 
 118. Id. at 2, 5. 
 119. Id. at 3. 
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2. Different Data Types and Release Considerations 
Notwithstanding this show of support, the Ft. Lauderdale 
participants acknowledged that rapid pre-publication data 
release might not be feasible or desirable in all situations, 
particularly for projects other than CRPs. In particular, the 
notion of a CRP, the primary goal of which is to generate a 
particular data set for general scientific use, is often 
distinguished from “hypothesis-driven” research in which the 
investigators’ primary goal is to solve a particular scientific 
question, such as the function of a specific gene or the cause of 
a specific disease or condition.120 In hypothesis-driven research, 
success is often measured by the degree to which a scientific 
question is answered rather than the completion of a 
quantifiable data set or other product. Thus, the early release 
of data generated by such projects would generally be resisted 
by the data generating scientists who carefully selected their 
experiments to test as yet unpublished theories. Giving such 
data away before their theories are finalized or published could 
potentially enable a competing group to “scoop” the originating 
group, a persistent fear among highly competitive scientists. 
3. Adoption by NHGRI 
As with the Bermuda Principles, the refinements agreed to 
in Ft. Lauderdale were widely adopted, both by NHGRI and the 
major sequencing laboratories.  The NHGRI 2003 policy, issued 
just a few weeks after the Ft. Lauderdale meeting, reiterates 
the agency’s commitment to the Bermuda Principles “for all 
types of large-scale DNA sequence data sets.”121 In the policy, 
NHGRI recognizes the need for data generators to achieve 
publications from the data they have released.122 Despite this 
acknowledgement, the agency declines to impose any time 
                                                          
 120. See, e.g., Kaye et al., supra note 10. An analogy to the distinction 
between CRP and hypothesis-driven projects in biomedical science may be 
drawn from geology. In geology, a CRP might be the U.S. Geological Survey’s 
creation of a geophysical map of a region for the use of all interested 
geologists, while a hypothesis-driven project might seek to determine whether 
shale oil can be extracted from a particular valley in that region. 
 121. Reaffirmation and Extension of NHGRI Rapid Data Release Policies:  
Large-Scale Sequencing and Other Community Resource Projects, NAT’L 
HUMAN GENOME RESEARCH INST. (Feb. 2003), 
http://www.genome.gov/10506537 [hereinafter NHGRI 2003 POLICY]. 
 122. Id. (“[T]he sequence producers have a legitimate interest in publishing 
peer-reviewed reports describing and analyzing the sequence they have 
produced.”). 
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limitation or other restriction on users of the released sequence 
data.  Instead, the policy strongly reaffirms NHGRI’s position 
that DNA sequence data “should be available for all to use 
without restriction” and urges data users to act in accordance 
with “standard scientific norms” and to acknowledge data 
generators in published analyses based on their data.123 These 
recommendations, though indicative of NHGRI’s desired policy, 
lack binding effect, which NHGRI acknowledges but fails to 
remedy, stating that “even if the sequence data are occasionally 
used in ways that violate normal standards of scientific 
etiquette, unconditional release of sequence data from large-
scale sequence production centers is a necessary risk set 
against the considerable benefits of immediate data release.”124 
This statement provides little comfort to data generators who 
are given no effective recourse if their data are used in a 
manner that violates these standards. 
4. The International HapMap Project, a New CRP 
Beginning in 2002, a group of scientists and funding 
agencies from Japan, the United Kingdom, Canada, China, 
Nigeria, and the United States began a project to develop a 
haplotype map of the human genome.125 The data release policy 
of the HapMap Project is based on the Ft. Lauderdale 
principles, and the project self-designates itself as a CRP.126 
Data generated by the project “[were] released rapidly into” 
publicly accessible databases,127 but access was subject to the 
user’s consent to the terms of a standardized, online click-wrap 
agreement.128 
                                                          
 123. Id. 
 124. Id. (emphasis added). 
 125. See generally The Int’l HapMap Consortium, The International 
HapMap Project, 426 NATURE 789, 790 (2003) (noting that a haplotype map 
shows genomic “markers” that tend to recur in groups). 
 126. Id. at 793. 
 127. Id. SNP data were deposited in the NIH’s dbSNP database (a public 
database), while genotype and haplotype data were made available through 
the project’s data coordination center. 
 128. Id. A click-wrap agreement (alternatively referred to as a “click-
through” or “click-to-accept” agreement or license) is “an electronic form 
agreement to which [a] party may assent by clicking an icon or a button or by 
typing in a set of specified words.” Christina L. Kunz et al., Click-Through 
Agreements:  Strategies for Avoiding Disputes on Validity of Assent, 57 BUS. 
LAW. 401 (2001–2002). Rebecca Eisenberg, who analogizes the HapMap 
Agreement to the open source software General Public License (GPL) raises 
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The HapMap Project took several affirmative steps to 
ensure that patents would not be filed by data generators, data 
users claiming haplotypes, or other data generated by the 
project.129 Most importantly, each user of HapMap data 
(including data generators) was expressly prohibited from 
restricting access to the HapMap database and, in particular, 
from filing patent applications on the haplotypes or other 
scientific data generated by the project.130 The HapMap 
Consortium’s non-patenting requirement was viewed with 
admiration by many, including policy makers at NHGRI.131 
As a corollary to the provisions of its click-wrap agreement, 
the HapMap Project adopted a “Data Release Policy,” setting 
forth the participants’ somewhat conclusory position that raw 
SNP and haplotype data lack “specific utility” necessary for 
patent protection.132 The Policy also stated that, because the 
Project will not relate genetic variants to medically relevant 
conditions, “results that might be patentable can be obtained 
only through additional studies not connected with the 
HapMap Project.”133 
5. The ENCODE Pilot Project 
The Encyclopedia of DNA Elements (ENCODE) pilot 
project was launched by NHGRI in 2003 as an effort to 
elucidate the biological functions of various genetic elements.134 
NHGRI issued a data release policy for the ENCODE pilot 
                                                          
questions about the enforceability of such agreements. Eisenberg, supra note 
47, at 1028. For a general discussion of the enforceability of click-wrap 
agreements, see generally GEORGE G. DELTA & JEFFREY H. MATSUURA, LAW OF 
THE INTERNET § 10.05 (2d ed. 2008). 
 129. See The International HapMap Consortium, supra note 125, at 793. 
 130. Registration for Access to the HapMap Project Genotype Database, 
INT’L HAPMAP PROJECT, http://hapmap.ncbi.nlm.nih.gov/cgi-perl/registration 
(last visited Jan. 18, 2011) [hereinafter HapMap Agreement]. 
 131. See ENCODE Project Data Release Policy (2003-2007), NAT’L HUMAN 
GENOME RESEARCH INST., http://www.genome.gov/12513440 (last visited Oct. 
18, 2010) [hereinafter ENCODE 2003 Pilot Policy]. (referring to the HapMap 
Project’s successful policy of discouraging “parasitic patents”). 
 132. Data Release Policy, INT’L HAPMAP PROJECT, 
http://www.hapmap.org/datareleasepolicy.html (last visited Jan. 18, 2011). 
 133. Id. Though unclear from the HapMap project web site, Rebecca 
Eisenberg reports that the Data Release Policy was adopted as late as 2004 
and was intended to supersede the click-wrap structure. Eisenberg, supra note 
47, at 1026. 
 134. The ENCODE Project Consortium, Identification and analysis of 
functional elements in 1% of the human genome by the ENCODE pilot project, 
447 NATURE 799 (2007). 
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project closely following the Ft. Lauderdale principles.135 The 
NHGRI designated the project as a CRP.136 As recommended in 
Ft. Lauderdale, users of the data were urged to cite the data 
generators in their analyses and to consider research 
collaborations with them.137 
With respect to intellectual property issues, the agency 
first acknowledges the requirements of the Bayh-Dole Act by, 
on one hand, stating that it has complied with those 
requirements and, on the other, expressing its view that patent 
protection for genomic sequence data is inappropriate.138 With 
this preface, NHGRI acknowledges that the data created by the 
ENCODE project will differ in character from the raw sequence 
data generated by the HGP and HapMap project. That is, the 
DNA sequence elements identified by ENCODE will, by 
definition, “have biological function, and therefore might be 
considered to have utility and be able to be patented.”139 
Constrained by Bayh-Dole from expressly requiring researchers 
to forego the opportunity to patent their federally-funded 
inventions, NHGRI strongly “encourages all ENCODE data 
producers to consider placing all information generated from 
their project-related efforts in the public domain . . . .”140 In 
addition, if grantees elect not to place their results in the public 
domain, the agency encourages them to consider “maximal use 
of non-exclusive licensing of patents to allow for broad access 
and stimulate the development of multiple products.”141 This 
language seems to represent NHGRI’s perception of the 
greatest extent of its ability to promote the public domain over 
patenting while remaining compliant with the letter of the 
Bayh-Dole Act. 
 
 
 
                                                          
 135. See ENCODE 2003 Pilot Policy, supra note 131. 
 136. Id. 
 137. Id. 
 138. Id. 
 139. Id. 
 140. Id. 
 141. Id. 
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D. EARLY PRIVATE SECTOR INITIATIVES 
In addition to the HGP and other public sector sequencing 
efforts described above, a number of private sector projects 
made substantial contributions to the genome commons, many 
with data release policies informed by the principles 
established in Bermuda and Ft. Lauderdale. 
1. The Merck Gene Index 
As early as 1994, pharmaceutical manufacturer Merck, 
collaborating with Lawrence Livermore National Laboratory 
and Washington University, compiled the so-called “Merck 
Gene Index,” a publicly accessible database of expressed 
sequence tags (ESTs).142 By 1998, the Merck Gene Index had 
released over 800,000 ESTs through GenBank.143 Merck’s 
stated reason for contributing this potentially valuable data to 
the public was the expansion of basic knowledge in the interest 
of combating disease.144 While this goal is laudable, it was 
generally acknowledged that another motivation for placing 
these ESTs into the public was the pre-emption of patent filings 
by biotech companies, several of which had already announced 
business plans that involved the patenting and licensing of 
ESTs and other genetic information.145 
2. The SNP Consortium 
An interesting and oft-cited parallel to the post-HGP 
government-funded projects discussed above is that of the SNP 
Consortium.  This non-profit entity was formed in 1999 by a 
                                                          
 142. See Press Release, Merck & Co., Inc., First Installment of Merck Gene 
Index Data Released to Public Databases: Cooperative Effort Promises to 
Speed Scientific Understanding of the Human Genome (Feb. 10, 1995), 
[hereinafter Merck Gene Index Press Release], available at 
http://www.bio.net/bionet/mm/bionews/1995-February/001794.html; see also 
supra notes 92–93and accompanying text (discussing ESTs and the patenting 
debate surrounding them). 
 143. DON TAPSCOTT & ANTHONY D. WILLIAMS, WIKINOMICS: HOW MASS 
COLLABORATION CHANGES EVERYTHING 166 (2006). 
 144. Merck Gene Index Press Release, supra note 142. 
 145. Marshall, supra note 82. Companies such as Incyte Pharmaceuticals 
in Palo Alto, California, and Human Genome Sciences in Rockville, Maryland, 
were then actively pursuing a business strategy of patenting, and licensing, 
ESTs and other genetic data. Id.;  See TAPSCOTT & WILLIAMS, supra note 143; 
Arti Kaur Rai, Regulating Scientific Research: Intellectual Property Rights and 
the Norms of Science, 94 NW. U. L. REV. 77, 134 (1999–2000). 
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group of ten pharmaceutical companies146 and the Wellcome 
Trust to identify and map genetic markers referred to as 
“single nucleotide polymorphisms” (SNPs) and to release the 
resulting data to the public domain.147 SNP data were publicly 
released on the Consortium’s web site on a quarterly, and later 
monthly, basis during the two-year research program, and also 
deposited in GenBank.148 The Consortium ultimately mapped 
1.4 million SNPs and created a genome-wide SNP-based 
human linkage map, all of which were made publicly available 
along with a number of query and search tools.149 Like the 
Merck Gene Index, the SNP Consortium aimed to generate 
data for the use of all researchers, unencumbered by patents.150 
It accomplished this goal by filing U.S. patent applications 
covering SNPs that it discovered and then contributing these 
                                                          
 146. The SNP Consortium Ltd. was incorporated in March 1999 with the 
following sponsoring (i.e., dues-paying) members: The Wellcome Trust 
Limited, Pfizer Inc, Glaxo Wellcome Inc., Hoechst Marion Roussel, Zeneca 
Inc., Hoffman-La Roche Inc., Novartis Pharmaceuticals Corporation, Bristol-
Myers Squibb Company, SmithKline Beecham Corporation, Bayer Corporation 
and Monsanto Corporation.  Technology giants Motorola, Inc. and 
International Business Machines Corporation joined as sponsoring members 
in November 1999 and Amersham Pharmacia Biotech Inc. became a 
sponsoring member in 2001.  Jorge Contreras, Personal Files (on file with 
author). 
 147. SNPs are instances in which single base pairs in the genome differ 
among individuals and occur roughly once per thousand base pairs. Though 
the presence of certain SNPs has been associated with diseases, the purpose of 
generating so-called SNP maps is to establish a uniform set of  “mile markers” 
along the vast genome.  See Arthur Holden, The SNP Consortium: Summary 
of a Private Consortium Effort to Develop an Applied Map of the Human 
Genome, 32 BIOTECHNIQUES 22 (2002). 
 148. See Holden, supra note 147, at 25–26 and SNP Fact Sheet, U.S. 
DEPARTMENT OF ENERGY GENOME PROGRAM, 
http://www.ornl.gov/sci/techresources/Human_Genome/faq/snps.shtml#when 
(last visited Jan. 18, 2011).  The SNP Consortium’s data is currently hosted on 
the International HapMap Project’s web site. 
 149. Holden, supra note 147, at 25–26. See also Gudmundur A. Thorisson 
& Lincoln D. Stein, The SNP Consortium website: past, present and future, 31 
NUCLEIC ACIDS RES. 124, 124–27 (2003) (providing a detailed description of 
how the public can utilize the consortium’s website). 
 150. See, e.g., Holden, supra note 147, at 26 (“[t]he overall IP objective is to 
maximize the number of SNPs that (i) enter the public domain at the earliest 
possible date, and, (ii) are free of third-party encumbrances such that the map 
can be used by all without financial or other IP obligations.”); TAPSCOTT & 
WILLIAMS, supra note 143, at 168 (noting consortium members’ concerns about 
biotech companies’ plans to patent SNPs and “sell them to the highest 
bidder.”). 
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applications to the public domain prior to issuance.151 This 
approach ensured that the Consortium’s discoveries would act 
as prior art defeating subsequent third-party patent 
applications, with a priority date extending back to the initial 
filings. The SNP Consortium’s innovative “protective” 
patenting strategy has been cited as a model of the private 
industry’s potential to contribute to the public genome 
commons.152 
E. SECOND GENERATION GENOMIC DATA RELEASE POLICIES 
In the years following the Ft. Lauderdale meeting, 
numerous large-scale genomic research projects have been 
launched with increasingly sophisticated requirements 
regarding data release. These policies implement their 
requirements through contractual mechanisms that are more 
tailored and comprehensive than the broad policy statements of 
the HGP era. Moreover, increasingly sophisticated database 
technologies have enabled the provision of differentiated levels 
of data access, the screening of user applications for data 
access, and improved tracking of data access and users. 
1. Genetic Association Information Network (GAIN) 
The Genetic Association Information Network (GAIN) was 
established in 2006 by the Foundation for the National 
Institutes of Health (FNIH), the NIH, and several 
corporations.153 GAIN’s purpose was to conduct GWA studies of 
                                                          
 151. The SNP Consortium’s patenting strategy included the filing of patent 
applications covering all mapped SNPs and then converting those applications 
into statutory invention registrations (SIRs) or abandoning the applications 
after publication. See Identification and Mapping of Single Nucleotide 
Polymorphisms in the Human Genome, U.S. Statutory Invention Registration, 
No. H2220 (filed Aug. 8, 2001); Identification and Mapping of Single 
Nucleotide Polymorphisms in the Human Genome, U.S. Statutory Invention 
Registration, No. H2220 (filed Nov. 21, 2002). 
 152. See, e.g., Marshall, supra note 82, at 1192 (noting the consortium’s 
“defensive move” deriving from the Merck Gene Index’s earlier strategy); 
Cook-Deegan & McCormack, supra note 96 (describing the consortium’s 
“unusual and sophisticated approach to keeping data in the public domain.”); 
Allen C. Nunnally, Intellectual Property Perspectives in Pharmacogenomics, 46 
JURIMETRICS 249, 252–53 (2006) (noting that the consortium members’ 
placement of the raw SNP map into the public domain did not necessarily 
preclude their, or anybody else’s, patenting of subsequent discoveries made 
using the basic research funded by the consortium). 
 153. See generally The GAIN Collaborative Research Group, New Models of 
Collaboration in Genome-wide Association Studies: The Genetic Association 
Information Network, 39 NATURE GENETICS 1045 (2007) (explaining the 
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the genetic basis for six common diseases.154 Data generators in 
the GAIN program were required to sign an applicant 
agreement agreeing to various program commitments, 
including “immediate” release of data generated by the 
project.155 Over the course of the three-year project, 
approximately 18,000 human DNA samples were genotyped.156 
The resulting data was deposited in the Database of Genotypes 
and Phenotypes (dbGaP) within the National Library of 
Medicine at NIH.157 
The dbGaP allows access to data on two levels: open and 
controlled.158 Open access is available to the general public via 
the Internet and includes non-sensitive summary data, 
generally in aggregated form.159 Researchers wishing to access 
data from the controlled portion of the database must register 
with and be approved by the GAIN Data Access Committee 
(DAC).160 They must also agree to keep the data secure, use it 
only for approved research purposes, refrain from patenting the 
data or conclusions drawn directly from the data, acknowledge 
data generators, and refrain from attempting to identify 
                                                          
selection and characteristics of initial GAIN studies, the structure of GAIN, 
and defining who has access to GAIN data). 
 154. The diseases studied were Attention Deficit Hyperactivity Disorder 
(ADHD), diabetic nephropathy in Type 1 diabetes, major depression, psoriasis, 
schizophrenia and bipolar disorder.  Genetic Association Information Network 
(GAIN), FOUND. FOR THE NAT’L INST. OF HEALTH, 
http://www.fnih.org/work/past-programs/genetic-association-information-
network-gain (last visited Oct. 28, 2010) [hereinafter FNIH Gain Information 
Sheet]. 
 155. The GAIN Collaborative Research Group, supra note 153, at 1048 
(Box 1). 
 156. Teri A. Manolio, Collaborative genome-wide association studies of 
diverse diseases: programs of the NHGRI’s office of population genomics, 10 
PHARMACOGENOMICS 235, 236 (2009). 
 157. The combination of phenotypic data with genomic data is critical to 
understanding disease and physiological traits having genetic influences. See 
generally DbGaP Overview, DBGAP-GENOTYPES & PHENOTYPES, 
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/about.html (last visited Oct. 
28, 2010). However, phenotypic data, which includes elements such as de-
identified subject age, ethnicity, weight, demographics, exposure, disease state 
and behavioral factors, are far more complex to record, search and correlate 
than raw sequence data deposited in GenBank.  Id. In addition to genotypic 
and phenotypic data, dbGaP can accommodate study documentation and 
statistical results, including linkage and association analyses. Id. 
 158. Id. 
 159. Id. 
 160. The Gain Collaborative Research Group, supra note 153, at 1049. 
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individual study participants.161 
Perhaps most importantly, the GAIN policy is the first 
genomic data release policy to introduce a temporal restriction 
on the users of the data (as opposed to the temporal release 
requirements imposed on data generators by the Bermuda 
Principles). That is, in order to secure a period of exclusive use 
and publication priority for the data generators, data users are 
prohibited from submitting abstracts and publications and from 
making presentations based on GAIN data for a specified 
embargo period.162 The duration of the embargo period for a 
given data set is identified in the relevant data repository and 
may vary by data set, but has generally been set at nine 
months.163 
2. The Cancer Genome Atlas (TCGA) 
In 2006, the National Cancer Institute (NCI) and NHGRI 
launched a pilot project to catalog genomic changes relating to 
cancer.164 The Cancer Genome Atlas (TCGA) project generates 
genomic sequence and related data, but also keeps track of 
large amounts of clinical data, including patient diagnosis, 
treatment history, and ongoing status.165 Due to the specialized 
nature of the project data, deposits are made in both dbGaP 
and a TCGA-specific database administered by NCI.166 
Given the potential for identifying individual patients from 
their genomic and phenotypic data, great attention was paid to 
controlling access to TCGA data.167 Like GAIN data, TCGA 
                                                          
 161. Data Use Certification Agreement, GENETIC ASS’N INFO. NETWORK 
(GAIN) (Dec. 3, 2008) 
https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?view_pdf&stacc=phs000021.v1.p1 
[hereinafter GAIN Data Use Agreement]. 
 162. The GAIN Collaborative Research Group, supra note 153, at 1049. 
 163. Id. 
 164. See generally Francis S. Collins & Anna D. Barker, Mapping the 
Cancer Genome, SCI. AM., Mar. 2007, at 50.  The pilot project is scheduled to 
conclude in October 2009. Id. 
 165. Types of Data, THE CANCER GENOME ATLAS DATA PORTAL, 
http://cancergenome.nih.gov/dataportal/data/about/types/clinical/ (last visited 
Oct. 28, 2010). 
 166. Data Use Certification Agreement, THE CANCER GENOME ATLAS PILOT 
PROJECT (Feb. 22, 2010) 
http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&view_pdf&stacc=phs000
178.v1.p1. 
 167. A multi-constituency workshop was convened in May 2006 to discuss 
proposed TCGA data access policies and practices. See generally Policies and 
Guidelines, THE CANCER GENOME ATLAS,  
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data is available in an open-access tier and a controlled-access 
tier.168 Open-access is provided for data that cannot be 
aggregated to generate an individually-identifiable dataset, 
whereas controlled-access enables researchers to access clinical 
and individually-unique data.169  Access to the controlled-access 
data tier requires the user’s acknowledgement of a Data Access 
Certification containing restrictions on research use, security, 
transferability, and other matters that are nearly identical to 
those in the GAIN agreement.170 One significant difference 
from the GAIN agreement, however, is the absence in the 
TCGA certification of a protected period for data generators.  
Thus, while data users are requested to acknowledge the TCGA 
in publications based on TCGA data,171 there is no embargo 
restriction on the right of data users to submit abstracts or 
publications derived from TCGA data. 
3. The NIH GWAS Policy 
In response to the growing number of GWA studies being 
conducted and the large amount of genomic data generated by 
such studies, in August 2007 the NIH released a new policy 
regarding the generation, protection and sharing of data 
generated by all federally-funded GWA studies.172 The NIH 
GWAS Policy requires that grantees submit descriptive 
information about each GWA study for inclusion in the “open 
                                                          
http://cancergenome.nih.gov/about/policies/informed_consent.asp (last visited 
Oct. 28, 2010) (detailing the many considerations taken into account in 
creating the policies for data access). 
 168. Data Access, THE CANCER GENOME ATLAS DATA PORTAL, 
http://cancergenome.nih.gov/dataportal/data/access/ (last visited Oct. 28, 
2010). 
 169. Id. 
 170. Compare Data Use Certification Agreement, supra note 166, with 
GAIN Data Use Agreement, supra note 153. 
 171. TCGA Data Use Certification, supra note 166, at 7. 
 172. Policy for Sharing of Data Obtained in NIH Supported or Conducted 
Genome-Wide Association Studies (GWAS), 72 Fed. Reg. 49290, 49294–97 
(Aug. 28, 2007) [hereinafter NIH GWAS Policy].  Though the HGP and other 
early genomic studies were conducted under the auspices of NHGRI, by 2006 
most of the NIH Institutes were funding genomic research and GWA studies of 
their own in support of their individual research missions. Modifications to 
Genome-Wide Association Studies (GWAS) Data Access, NAT’L INST. OF 
HEALTH (Aug. 28, 2008) 
http://grants.nih.gov/grants/gwas/data_sharing_policy_modifications_2008082
8.pdf [hereinafter Modifications to GWAS Data Access]. 
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access” portion of dbGaP.173 Grantees are also “strongly 
encouraged” to submit study results, including phenotypic, 
exposure and genotypic data, for inclusion in the “controlled 
access” portion of the database “as soon as quality control 
procedures have been completed.”174 
Among the principal concerns raised concerning GWAS 
data were those surrounding the public release of phenotypic or 
clinical information that could eventually be traced back to 
individual subjects.175 To address this concern, the NIH GWAS 
Policy requires that GWAS data be de-identified in accordance 
with HIPAA guidelines.176 Moreover, the data in the controlled-
access portion of the database may be released only after 
approval of the proposed research use by a Data Access 
Committee177 and then only under a signed Data Use 
Certification that contains stringent protective clauses.178 
Finally, the NIH sets forth its position that a request under the 
                                                          
 173. Descriptive information includes the study protocol, questionnaires, 
manuals, variables measured and other supporting documentation.  NIH 
GWAS Policy, supra note 172, at 49, 295.  The NIH GWAS Policy was 
amended in August, 2008, following the publication of a scientific paper 
demonstrating that inferences regarding individual identity could be drawn by 
analyzing allele frequency data in aggregated genomic data sets and other 
statistical techniques.  Modifications to GWAS Data Access, supra note 172. 
Due to concerns relating to potential identification of GWAS subjects, NIH 
withdrew certain GWAS-generated SNP data from the publicly-accessible 
portions of dbGaP and certain NCI databases and placed them in the 
controlled-access portions of these databases. Id. 
 174. NIH GWAS Policy, supra note 172, at 49295.  As in the GAIN Policy, 
access to the controlled-access portion of the database is regulated by a Data 
Access Committee and carries stringent protective measures on the use of 
data.  Id. at 49296. 
 175. Id. at 49292 (summarizing public concerns over the availability of 
personally-identifiable data).  The NIH acknowledges that technologies either 
in existence or likely to be available soon would make the identification of 
individuals from raw genotypic and phenotypic data “feasible and increasingly 
straightforward.”  Id. 
 176. Id. at 49295 (citing the HIPAA Privacy Rule, 45 CFR 164.514(b)(2)). 
 177. The DAC is comprised primarily of NIH staff with expertise in the 
relevant scientific disciplines, data privacy and data subject protection.  Id. at 
49296. 
 178. Like the certification required under the GAIN program, see supra 
Section III.E.1, the GWAS Data Use Certification requires researchers and 
their institutions to agree, among other things, to: use data only for the 
approved research purpose, protect data confidentiality, implement 
appropriate data security measures, not attempt to identify individual data 
subjects, not sell any data, not share data with third parties, and to report 
violations to the committee.  NIH GWAS Policy, supra note 172, at 49296. 
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Federal Freedom of Information Act (FOIA)179 for the release of 
individually-identifiable GWAS information would constitute 
an “invasion of personal privacy” under FOIA and will be 
denied by NIH.180 
The GWAS Policy addresses the publication priority 
concerns of data generators by stating an expectation that 
users of GWAS data refrain from submitting their analyses and 
conclusions for publication, or otherwise presenting them 
publicly, during an “exclusivity” period of up to twelve months 
from the date that the data set is made available.181 The agency 
also expresses a “hope” and expectation that “genotype-
phenotype associations identified through NIH-supported and 
NIH-maintained GWAS datasets and their obvious 
implications will remain available to all investigators, 
unencumbered by intellectual property claims.”182 It goes on to 
explain that “[t]he filing of patent applications and/or the 
enforcement of resultant patents in a manner that might 
restrict use of NIH-supported genotype-phenotype data could 
diminish the potential public benefit they could provide.”183 
However, in an effort to show some support for patent seekers, 
the GWAS Policy also “encourages patenting of technology 
suitable for subsequent private investment that may lead to 
the development of products that address public needs.”184 
4. International SAE Consortium 
Since the successful completion of the SNP Consortium 
project, several other privately-funded research collaborations 
have adopted data release models that are similarly intended 
to place large quantities of genomic data into the public 
domain.  One of these is the International Serious Adverse 
                                                          
 179. See generally Federal Freedom of Information Act, 5 U.S.C. § 552 
(2006). 
 180. NIH GWAS Policy, supra note 172, at 49292 (citing FOIA Exemption 
6, 5 U.S.C. §552(b)(6)). 
 181. This exclusivity period was originally nine months when the GWAS 
Policy was released for public comment, but was subsequently lengthened to 
twelve months.  Request for Information (RFI): Proposed Policy for Sharing 
of Data obtained in NIH supported or conducted Genome-Wide Association 
Studies (GWAS), NAT’L INST. OF HEALTH (Aug. 30, 2006) 
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-06-094.html. 
 182. NIH GWAS Policy, supra note 172, at 49296. 
 183. Id. at 49297 
 184. Id. at 49296. 
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Event Consortium (iSAEC), a group of pharmaceutical 
companies formed in 2007 to fund research toward the 
identification of DNA markers for drug-induced serious adverse 
events.185  The Consortium works with academic collaborators 
to collect DNA samples and associated phenotypic data and to 
then conduct GWA studies, targeted sequencing, and statistical 
analyses to identify potential markers and associations of 
interest.186 Since its formation, iSAEC studies have identified 
DNA markers relating to drug-induced liver injury (DILI)187 
and serious skin rash (SSR). The iSAEC seeks to minimize 
patent encumbrances on genetic markers and associations that 
it identifies via a “protective” patent strategy modeled on that 
of the SNP Consortium. To date, patent applications claiming 
various DNA markers relevant to DILI and SSR have been 
filed with the intention that they will be abandoned following 
publication.188 Like the GAIN and other policies discussed in 
this section, the iSAEC imposes various security, research 
purpose, and non-patenting restrictions on data that is publicly 
released. It also secures for data-generating scientists a period 
of exclusivity (up to twelve months) during which they have 
sole access to the data.189 During this time, they have the 
ability to analyze data and prepare papers for publication 
without the threat of being scooped by competing groups. While 
the research funded by iSAEC would not typically be 
considered a “community resource project” as defined in Ft. 
Lauderdale (as its goal is not the creation of a large, generally-
applicable data set),190 the Consortium has still committed to 
release its data to the public, albeit on a delayed basis. This 
approach illustrates an effective compromise among the 
interests of data generators in a hypothesis-driven research 
                                                          
 185. iSAEC’s Background and Organizational Structure, INT’L SAE 
CONSORTIUM, http://www.saeconsortium.org/ (last accessed Oct. 28, 2010). 
 186. Id. 
 187. See generally Ann K. Daly et al., HLA-B*5701 Genotype is a Major 
Determinant of Drug-Induced Liver Injury due to Flucloxacillin, 41 NATURE 
GENETICS 816 (July 2009) (discussing the genetic basis for susceptibility to 
drug-induced liver injury from flucloxacillin). 
 188. Biomarkers for Drug-Induced Liver Injury, U.S. Patent App. 
12/505,058 (filed Jul. 17, 2009); Biomarkers for Serious Skin Rash, U.S. 
Patent App. 61/112,983 (filed Nov.10, 2009); Biomarkers for Serious Skin 
Rash, U.S. Patent App. 61/168,875 (filed Nov. 10, 2009). 
 189. Int’l SAE Consortium Ltd., DATA RELEASE AND INTELLECTUAL 
PROPERTY POLICY (last amended Nov. 5, 2009) (on file with author). 
 190. See supra Section III.C.1. 
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model and the community of data users and funders.191 
5. The Full ENCODE Project and modENCODE 
In 2007 NHGRI expanded the ENCODE pilot project192 to 
cover the entire human genome and launched a corollary 
project (modENCODE) to identify the functional genomic 
elements of two common model organisms, the roundworm (C. 
elegans) and fruit fly (Drosophila melanogaster).193 This 
expansion involved an overhaul of the 2003 ENCODE data 
release policy and resulted in a new policy in 2008 covering 
both the expanded ENCODE project and modENCODE.194 The 
ENCODE 2008 Policy has much in common with its 2003 
predecessor, though it also introduces some of the policy 
features added by the later GAIN and GWAS policies. Thus, 
while the ENCODE 2008 Policy continues to use the Ft. 
Lauderdale terminology in designating itself a “community 
resource project,” it also recommends a nine month embargo 
period during which users of released data are requested not to 
publish or present results based on that data.195 
The ENCODE 2008 Policy is among the most complex data 
release policies to date, as it distinguishes between published 
and unpublished data, verified and unverified data, and offers 
several examples of the data use implications for different 
types of studies conducted with ENCODE data.196 The length 
and complexity of the policy evidences the desire of the agency 
and the participants for clear guidelines and avoidance of 
misunderstandings regarding the release of data, as the 
diversity of participants, organisms, and data types has 
expanded dramatically beyond those originally considered by 
the framers of the Bermuda Principles. 
                                                          
 191. The compromises and negotiation strategy inherent in this approach 
is discussed in greater detail in Contreras, Data Sharing, supra note 5, at 11. 
 192. See supra Section III.C.5. 
 193. See Susan E. Celniker et al., Unlocking the Secrets of the Genome, 459 
NATURE 927 (2009) (describing the modENCODE project methodology and 
goals). 
 194. ENCODE Consortia Data Release, Data Use, and Publication Policies 
(2008), NAT’L HUMAN GENOME RESEARCH INST., 
http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolic
yFinal2008.pdf [hereinafter ENCODE 2008 Policy]. 
 195. Id. at 4. 
 196. Id. at 5–7. 
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F. POLICIES OUTSIDE THE UNITED STATES 
Although the HGP and subsequent genome sequencing 
projects relied on international cooperation and collaboration, 
the data release policies adopted by groups outside the United 
States have differed in material ways from corresponding 
policies adopted by NIH and NHGRI. In particular, non-U.S. 
funding agencies have generally exhibited less concern with 
patenting issues and have remained more flexible with respect 
to the timeframes for both release of data by data generators 
and embargo periods on publication for data users.197 A few 
examples of recent non-U.S. data release policies are described 
below. 
1. Genome Canada 
Genome Canada, a participant in the HGP, adopted its 
first formal data release policy in 2005.198 While acknowledging 
the Ft. Lauderdale principles, the Canadian policy does not 
adopt the 24-hour release requirement set forth in the earlier 
Bermuda Principles. With respect to data generators, Genome 
Canada “expects data to be released and shared no later than 
the original publication date” of the researchers’ results, 
provided that all data must be released “without restriction” by 
the end of a project.199 For patents, Genome Canada “recognizes 
the need to protect patentable and other proprietary data” and, 
thus, requires that the data generators’ obligation to release 
data occur upon the publication or the filing of a patent 
application, whichever is earlier.200 
2. Wellcome Trust Case Control Consortium (WTCCC) 
The Wellcome Trust is the largest charity in the United 
Kingdom and the second-largest biomedical research funding 
charity in the world. Since the beginning of the HGP, the 
                                                          
 197. The reason for this divergence is not clear, though it is possible that 
the absence of an equivalent to the Bayh-Dole Act in most countries, as well as 
a patenting landscape that is generally more restrictive outside the U.S., has 
made patent and data release issues less central to policy discussions outside 
the U.S. 
 198. Genome Canada, DATA RELEASE AND RESOURCE SHARING (Sept. 18, 
2008), available at 
http://www.genomecanada.ca/medias/PDF/EN/DataReleaseandResourceShari
ngPolicy.pdf. 
 199. Id. 
 200. Id. (also allowing for extensions of up to 90 days in the event of 
“extenuating circumstances”). 
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Wellcome Trust has supported genomics initiatives both 
through direct funding and through its Sanger Institute in 
Cambridge, England, a leading sequencing center.201 In 2006, 
the Trust funded a large-scale GWA study of seven complex 
human diseases that was conducted by more than fifty research 
groups from institutions across the United Kingdom.202 The 
study generated a large quantity of data, including aggregated 
and individual-level genotypic and phenotypic information. 
Most of this data was made available to the public in 
accordance with the Ft. Lauderdale Principles, and the project 
self-designated itself as a CRP.203 
 In order to ensure appropriate use of released data, the 
WTCCC requires all prospective data users to apply to the 
Consortium’s Data Access Committee and sign a written Data 
Access Agreement.204 Access to data is granted only to qualified 
investigators for “appropriate use,” as determined by the 
committee.205 The data access agreement requires security, 
acknowledgement, transfer, and use restrictions comparable to 
those found in the GAIN and other recent policies.206 It also 
includes some restrictions that are specific to the study 
samples, such as a prohibition on any use of data from the 1958 
British Birth Cohort for commercial purposes.207 The 
agreement does not, however, contain any specific embargo on 
publication or any restriction on patenting activity. 
                                                          
 201. See generally WELLCOME TRUST, 
http://www.wellcome.ac.uk/index.htm (last visited Oct. 26, 2010). 
 202. The main study covered 2,000 cases and 3,000 shared controls drawn 
primarily from British subjects for the following seven conditions: bipolar 
disorder, coronary artery disease, Chron’s disease, hypertension, rheumatoid 
arthritis, type 1 diabetes and type 2 diabetes. The Wellcome Trust Case 
Control Consortium, supra note 41. 
 203. Publications Policy, WELLCOME TRUST CASE CONTROL CONSORTIUM, 
https://www.wtccc.org.uk/ccc1/publications_policy_ext.shtml (last visited Oct. 
26, 2010). 
 204. See WTCCC: Access to Genotype Data, WELLCOME TRUST CASE 
CONTROL CONSORTIUM, 
https://www.wtccc.org.uk/docs/CDAC_Guidelines_and_Information_July09.pdf 
(last visited Oct. 26, 2010); Data Access Agreement, THE WELLCOME TRUST 
CASE CONTROL CONSORTIUM, 
https://www.wtccc.org.uk/docs/Data_Access_Agreement_v15.pdf (last visited 
Oct. 26, 2010). 
 205. WTCCC: Access to Genotype Data, supra note 204, at §4. 
 206. Data Access Agreement, supra note 204. 
 207. Id. at §2. 
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3. UK Medical Research Council 
In 2008 the United Kingdom’s Medical Research Council 
(MRC) released a comprehensive set of guidelines surrounding 
release of data from MRC-funded research.208 In a set of broad 
“data access principles,” the MRC announces that data 
generated by publicly-funded research are a public good and, as 
such, “must be made available for new research purposes in a 
timely, responsible manner.”209 Following the reasoning behind 
the Ft. Lauderdale principles, the MRC states that access to 
data “must balance the interests of data creators, custodians, 
users and data subjects,”210 and acknowledges that “limited, 
defined” periods of exclusive use “will often be justifiable.”211 
Beyond these broad pronouncements, however, the MRC gives 
little specific guidance with respect to the timing or manner of 
data release. 
Like the WTCCC guidelines, the MRC guidelines place a 
high value on formal, written agreements to govern the 
relationships between data generators and data users. Such 
agreements “must” be used if restrictions on the use of data are 
to be imposed and are “particularly important” when 
publication rights and intellectual property are implicated.212 
The MRC, however, by and large allows individual parties to 
define the specific requirements of their data sharing 
agreements and does not attempt to impose over-arching rules 
regarding the timing of data release. 
 
 
                                                          
 208. Principles for Access to, and Use of, MRC Funded Research Data, 
MEDICAL RESEARCH COUNCIL 
http://www.mrc.ac.uk/consumption/groups/public/documents/content/mrc00375
9.pdf (last visited Oct. 26, 2010) (Because the MRC broadly addresses 
biomedical research across many fields, the MRC guidelines do not focus on 
genomic data, nor do they expressly reference the Bermuda or Ft. Lauderdale 
principles, despite MRC’s participation in the original Bermuda meeting). 
 209. Id. at 1. 
 210. Id. 
 211. Id. at 4. 
 212. Id. at 5 para. 8. 
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G. RECENT DEVELOPMENTS IN RAPID PRE-PUBLICATION DATA 
RELEASE 
1. Amsterdam: Proteomics Joins the Fray 
The success and broad adoption of genomics data release 
policies incorporating the Bermuda and Ft. Lauderdale 
Principles have recently led scientists in related fields to 
consider the adoption of analogous principles in their own 
research.  One prominent example occurred in 2008, when the 
NCI convened a meeting of proteomics213 researchers in 
Amsterdam to “identify and address potential roadblocks to 
rapid and open access to [proteomics] data.”214 
Participants identified technical, infrastructure, and policy 
challenges to the rapid release of proteomic data. Technical 
challenges included the wide variety of disparate platforms and 
techniques used to generate proteomic data, making “raw” data 
from experimental instruments difficult to interpret by 
scientists unfamiliar with or lacking access to the instruments 
used to generate the data.215 Proteomics also lacks the 
established public database infrastructure of genomics. 
Whereas DNA sequence data can be deposited readily in 
GenBank, the EMBL, or DDBJ and is often deposited in all 
three, there is no common public data repository for proteomic 
data, and existing proteomic databases suffer from inconsistent 
and sometimes incompatible data formats.216 Finally, unlike 
genomics, in which the entire field focused for several years on 
the single HGP project, proteomics research lacks a unifying 
policy core, and proteomics-focused journals have each 
developed their own, sometimes inconsistent, guidelines for 
                                                          
 213. Proteomics is the study of protein structures.  Unlike DNA sequences, 
which are linear arrangements of the four basic nucleotides, A, C, T and G, 
proteins consist of intricately-folded, three-dimensional structures formed 
from twenty different amino acids.  Unlike today’s relatively straightforward 
and automated DNA sequencing technologies, the techniques for elucidating 
protein structures include electrophoresis, various forms of mass spectrometry 
and an increasing number of other methods.  See generally LESK, supra note 1, 
at 312–22. 
 214. Henry Rodriguez et al., Recommendations From the 2008 
International Summit on Proteomics Data Release and Sharing Policy:  A 
Summit Report, 8 J. PROTEOMICS RES. 3689 (2009). 
 215. See id. at 3689–90. 
 216. Id. at 3690.  Existing proteomic databases include GPMDB, 
UniProtKB, Peptide Atlas, PRIDE and NCBI’s Peptidome.  Id. 
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data submission.217 
Notwithstanding these difficulties, the Amsterdam 
participants articulated six data release and sharing principles 
that reflect the spirit of the Bermuda and Ft. Lauderdale 
Principles, but which lack the specificity of the genomics 
policies. The six Amsterdam principles are: (1) Timing (should 
depend on the nature of the effort generating the data, but in 
no event should be later than publication or, for community 
resource projects, following appropriate quality assurance 
procedures), (2) Comprehensiveness (full raw data sets should 
be released together with associated metadata and quality 
data), (3) Format (standardized formats are encouraged), (4) 
Deposition to repositories (central repositories for proteomic 
data should be established), (5) Quality metrics (central 
repositories should develop metrics for assessing data quality), 
and (6) Responsibility (scientists, funding agencies, and 
journals share responsibility for ensuring adherence to 
community data release standards).218 
2. The Toronto Data Release Workshop 
In 2009, more than a hundred scientists, journal editors, 
legal scholars, and representatives of governmental and private 
funding agencies met in Toronto to assess the current state of 
rapid pre-publication data release and the applicability of the 
Bermuda Principles in projects well beyond the generation of 
genomic sequence data.219 The participants reaffirmed a 
general community commitment to rapid pre-publication data 
release, expanding the scope of projects as to which of these 
principles should apply to all biomedical datasets having 
“broad utility, are large in scale . . . and are ‘reference’ in 
character.”220 Specifically, in addition to genomic and proteomic 
studies, they cited structural chemistry, metabolomics, and 
RNAi datasets, as well as annotated clinical resources such as 
cohorts, tissue banks, and case-control studies.221 
The expansion of rapid pre-publication data release 
principles beyond genomics and proteomics projects, which 
often have as their ultimate goal the generation of a large data 
                                                          
 217. Id. 
 218. Id. at 3690–91. 
 219. See Toronto Report, supra note 66. 
 220. Id. at 168. To some degree, this characterization is a restatement of 
the Ft. Lauderdale definition of “community resource projects”. 
 221. Id. 
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set, to these other areas necessarily raises issues concerning 
the appropriateness of rapid data release in hypothesis-driven 
research. Accordingly, the Toronto participants concurred that, 
while funding agencies should require rapid pre-publication 
data release for “broad utility” projects, rapid data release 
“should not be mandated” for projects that are generally 
hypothesis-driven.222 The Toronto participants also addressed 
the priority concerns of data generators versus data users, 
observing anecdotally that data users have in many cases 
published papers based on publicly-released data sets before 
the publication of the data generators’ papers analyzing the 
data sets themselves, and that this situation caused no “serious 
damage” to the data generators’ subsequent publications.223 
Nevertheless, the participants acknowledged the acceptability 
of a “protected period” during which data users could be 
restricted from publishing on released data sets, cautioning, 
however, that this period should never exceed one year.224 The 
Toronto participants produced a set of “best practices” 
embodying these principles and applying them to the three 
constituencies originally identified in Ft. Lauderdale—funding 
agencies, data generators and data users—as well as to the 
scientific journals, which were urged to monitor and provide 
guidance relating to data release issues.225 
Discussions in Toronto also addressed issues of intellectual 
property. In particular, it was observed that, as data sets 
subject to rapid pre-publication release expand beyond genomic 
and proteomic “basic science” and begin to embody greater 
functional content and clinical utility, the patentability of this 
information will be less open to debate, and the early release of 
such information will have a greater impact on the data 
generators’ ability to secure patent protection with concomitant 
implications for U.S. funding agencies subject to Bayh-Dole 
requirements.226 Given the controversial nature of this subject 
and the lack of consensus on this issue, the subject of 
intellectual property was ultimately excluded from the 
published meeting report. It is inevitable, however, that 
                                                          
 222. Id. at 169. 
 223. Id. at 169–70. 
 224. Id. at 170. 
 225. Id. 
 226. Author’s personal notes, The Toronto Data Release Workshop (May 
13-14, 2009) (on file with author). 
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intellectual property issues will play an increasingly important 
role in discussions of rapid pre-publication data release in fields 
of medical significance. 
3. New Policies and Projects 
The influence of the Bermuda/Ft. Lauderdale Principles 
has been lasting and pervasive. The list of new biomedical 
research projects that are currently developing or have recently 
adopted data release policies based on these principles or their 
progeny is too long to list here, but includes projects such as the 
1000 Genomes Project,227 the International Cancer Genome 
Consortium,228 and the Human Microbiome Project.229 NIH and 
NHGRI are in the process of considering further revisions to 
their institutional data release policies and collecting feedback 
from various stakeholder groups.230 Though the result of this 
latest round of revisions have not yet been released, it is likely 
that any new NIH data release policy will continue to refine the 
rules of rapid pre-publication data release to take into account 
the policy considerations and objectives described above. 
IV. POLICY CONSIDERATIONS IN GENOMIC DATA 
RELEASE POLICIES 
A. ELEMENTS OF POLICY DESIGN 
The preceding Section describes the major genomics-
related data release milestones and policies from the beginning 
of the HGP through today, a span of nearly two decades. Table 
1 below summarizes the manner in which each of these policies 
handles issues relating to the speed of data release, restrictions 
on data use, and intellectual property. 
 
 
                                                          
 227. See 1000 Genomes Data and Sample Information, 1000 GENOMES, 
http://www.1000genomes.org/page.php?page=data (last visited Oct. 28, 2010). 
 228. See INTERNATIONAL CANCER GENOME CONSORTIUM, GOALS, 
STRUCTURES, POLICIES & GUIDELINES 15 (2008), available at 
http://www.icgc.org/files/icgc/ICGC_April_29_2008_en.pdf. 
 229. See HMP Data Release and Resource Sharing Guidelines for Human 
Microbiome Project Data Production Grants, NIH COMMON FUND, 
http://commonfund.nih.gov/hmp/datareleaseguidelines.asp (last visited Oct. 
28, 2010). 
 230. National Institutes of Health, Notice on Development of Data Sharing 
Policy for Sequence and Related Genomic Data (Oct. 19, 2009), available at 
http://grants1.nih.gov/grants/guide/notice-files/NOT-HG-10-006.html. 
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Table 1: Comparative Summary of Genomics Data 
Release Policies 
 Type of 
Data 
Release 
Speed 
User 
Restrictio
ns 
Patent 
Considerat
ions 
NIH-DOE 
1992 
Guidelines 
Materials 
and data 
produced 
by the 
HGP231 
Within 6 
months 
after 
generation
232 
None233 IP 
protection 
“may be 
needed” for 
some data 
and 
materials234 
Bermuda 
Principles 
(1996) 
Initial 
genome 
sequence 
reads > 
1Kb235 
24 hours 
after 
generation
236 
None237 Not 
specified238 
NHGRI 
1996 Policy 
Human 
genomic 
DNA 
sequence 
data 
produced 
under the 
HGP239 
As rapidly 
as 
possible240 
None241 “raw human 
genomic 
DNA 
sequence . . . 
is an 
inappropriat
e material 
for patent 
filing”242 
                                                          
 231. NIH/DOE Guidelines, supra note 84. 
 232. Id. 
 233. Id. 
 234. Id. 
 235. Bermuda Principles, supra note 6. Initial genome sequence reads were 
increased to 2 Kb under the Bermuda 1997 Report. Id.. 
 236. Contreras, Prepublication Data Release, supra note 5, at 393. 
 237. Id. 
 238. See id. 
 239. NHGRI 1996 POLICY, supra note 107. 
 240. Id. 
 241. Id. 
 242. Id. 
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 Type of 
Data 
Release 
Speed 
User 
Restrictio
ns 
Patent 
Considerat
ions 
NHGRI 
1997 Policy 
Large-scale 
genomic 
DNA 
sequence 
data243 
24 hours 
after 
generation
244 
None245 Not 
specified246 
SNP 
Consortiu
m (1998)247 
SNP map 
and 
association 
data248 
Monthly/q
uarterly 
releases to 
web site249 
None250  protective 
filing 
strategy to 
release data 
to public 
domain251 
NHGRI 
2000 Policy 
Sequence 
trace data 
and 
ancillary 
information
252 
Deposited 
weekly 
into the 
NCBI 
Trace 
Repository
253 
Users may 
not use 
data for the 
initial 
publication 
of the 
complete 
genome 
sequence 
assembly 
or other 
large-scale 
analyses254 
Not 
specified255 
                                                          
 243. NHGRI 1997 POLICY, supra note 107. 
 244. Id. 
 245. Id. 
 246. See id. 
 247. Holden, supra note 147 at 22–26. 
 248. Id. 
 249. Id. at 26. 
 250. See id. at 22–23. 
 251. Id. at 26. 
 252. NHGRI 2000 Policy, supra note 112. 
 253. Id. 
 254. Id. 
 255. See id. 
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 Type of 
Data 
Release 
Speed 
User 
Restrictio
ns 
Patent 
Considerat
ions 
Ft. 
Lauderdale 
Principles 
(2003) 
All data 
from 
Community 
Resource 
Projects256 
Reaffirms 
Bermuda 
Principles 
for 
sequence 
assemblies 
> 2kB257 
Citation of 
data 
producers
258 
Not 
specified259 
NHGRI 
2003 Policy 
Large-scale 
sequence 
data260 
24 hours 
after 
generation
261 
Citation of 
data 
producers
262 
Not 
specified263 
Intl. 
HapMap 
Project 
(2003)  
SNP and 
Haplotype 
data264 
Rapidly265 Citation of 
data 
producers
266 
User click-
wrap 
agreement 
prohibits 
filing of 
patent 
applications 
on project 
data or uses 
thereof, 
unless unre-
stricted use 
is allowed267 
                                                          
 256. Ft. Lauderdale Principles, supra note 115. 
 257. Id. 
 258. Id. 
 259. See id. 
 260. NHGRI 2003 POLICY, supra note 121. 
 261. Id. 
 262. Id. 
 263. See id. 
 264. The Int’l HapMap Consortium, supra note 125. 
 265. Id. 
 266. Id. 
 267. Id.; HapMap Agreement, supra note 130. 
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 Type of 
Data 
Release 
Speed 
User 
Restrictio
ns 
Patent 
Considerat
ions 
ENCODE 
Pilot (2003)  
Various 
data types 
generated 
by the 
project268 
Deposited 
as soon as 
data is 
verified269 
Citation of 
data 
producers
270 
NHGRI 
encourages 
all data 
producers to 
consider 
placing 
information 
in the public 
domain271 
Wellcome 
Trust Case 
Control 
Consortiu
m 
(WTCCC) 
(2006)  
GWA study 
data272  
Not 
specified
273 
Signed 
data access 
agreement 
Citation of 
data 
producers; 
Security, 
transfer 
and use 
restrictions
274 
None275 
                                                          
 268. ENCODE 2003 Pilot Policy, supra note 131. 
 269. Id. 
 270. Id. 
 271. Id. 
 272. Publications Policy, supra note 203. 
 273. See id. 
 274. WTCCC: Access to Genotype Data, supra note 204. 
 275. See id.; Publications Policy, supra note 203. 
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 Type of 
Data 
Release 
Speed 
User 
Restrictio
ns 
Patent 
Considerat
ions 
GAIN 
(2006)  
GWA study 
data276 
Immediate
277 
Data use 
certificatio
n278 
Variable-
length 
embargo on 
publication 
and 
presentatio
n of data 
(generally 9 
months),279
Security, 
transfer 
and use 
restrictions
280 
Data users 
agree not to 
pursue 
patents that 
would block 
access to 
data or 
conclusions 
drawn 
directly from 
data281 
The Cancer 
Genome 
Atlas 
(TCGA) 
(2006) 
Tumor 
genomic 
and clinical 
data282 
As rapidly 
as 
possible283 
data use 
certificatio
n284 
Security 
and 
transfer285  
restrictions 
Urges users 
to avoid 
making IP 
claims286 
                                                          
 276. The GAIN Collaborative Research Group, supra note 153, at 1045. 
 277. Id. at 1048. 
 278. Id. at 1049. 
 279. Id. 
 280. Id. at 1046. 
 281. Id. at 1050. 
 282. Types of Data, supra note 165. 
 283. Data Use Certification, supra note 166, at 4. 
 284. Id. 
 285. Id. at 2–3. 
 286. Id. 
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 Type of 
Data 
Release 
Speed 
User 
Restrictio
ns 
Patent 
Considerat
ions 
NIH GWAS 
Policy 
(2007)  
GWA study 
data287 
Strong 
encourage
ment to 
submit 
data as 
soon as 
quality 
control 
procedure
s 
completed
288 
Signed 
data use 
certificatio
n289 
12-month 
embargo 
expectation 
on 
publication 
and 
presentatio
n of 
data,290 
Citation of 
data 
producers;
291 
Security, 
transfer 
and use 
restrictions
292 
Patenting of 
results 
discouraged
293 
                                                          
 287. 72 Fed. Reg. 49290, 49290 (Aug. 28, 2007). 
 288. Id. at 49293. 
 289. Id. at 49297. 
 290. Id. at 49294. 
 291. Id. 
 292. 72 Fed. Reg. 49290, 49296 (Aug. 28, 2007). 
 293. Id. 
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 Type of 
Data 
Release 
Speed 
User 
Restrictio
ns 
Patent 
Considerat
ions 
Intl. SAE 
Consortiu
m (2007) 294 
Human 
genotypic 
and 
phenotypic 
data 
12 months 
after data 
validation 
Signed 
member-
ship 
agreement 
Up to 9-
month 
embargo on 
publication 
and 
presentatio
n of data 
Citation of 
data 
producers; 
Security, 
transfer 
and use 
restrictions 
Data users 
agree not to 
pursue 
patents that 
would block 
access to 
data or 
conclusions 
drawn 
directly from 
data 
ENCODE + 
modENCO
DE (2008)  
Various 
data types 
generated 
by the 
project295 
Deposited 
as soon as 
data is 
verified296 
9-month 
embargo on 
publication 
and 
presentatio
n of data297 
Citation of 
data 
producers
298 
NHGRI 
monitoring 
of patenting 
activity and 
potential 
consid-
eration of 
click-wrap 
agreements 
(e.g.,  
HapMap 
Project299) 
 
                                                          
 294. See supra Part III.E.4. 
 295. The ENCODE Project Consortium, supra note 134, at 799. 
 296. ENCODE 2003 Pilot Policy, supra note 131. 
 297. ENCODE 2008 Policy, supra note 194, at 1. 
 298. Id. at 4. 
 299. Compare id. at 6–9, with HapMap Agreement, supra note 130. 
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B. POLICY DESIGN TRENDS 
Even a cursory inspection of Table 1 reveals several points 
regarding the evolution of genomics data release policies over 
the past two decades. Perhaps most obviously, these policies 
have grown more detailed and complex over time. The reasons 
for this growth are not difficult to guess. The Bermuda 
Principles introduced a sea change to scientific data release. 
Despite their groundbreaking significance and lasting 
influence, the Bermuda Principles were drafted to address one 
specific type of data (genomic sequence reads) generated by a 
specific, unique project (the HGP).300 It soon became clear that, 
while the spirit and intent of the Bermuda Principles were 
attractive to many, the extension of these principles to different 
projects and data types required additional explication and, in 
some cases, compromise. Below is a summary of the ways in 
which policy designers addressed the various policy 
considerations associated with the genome commons over this 
period. 
1. Protection of Human Subject Data 
Because the goal of the HGP was to generate a baseline 
map of the human genome without regard to the particular 
physiological and pathological traits associated with genetic 
variation among individuals, the genomic sequence data 
generated by the HGP was anonymous and retained no 
association with the individual subjects whose DNA was being 
sequenced.301 Similar characteristics applied to data generated 
by the HapMap Project302 and the SNP Consortium.303 These 
data were intended to elucidate non-individualized information 
applicable to the human genome generally. Accordingly, 
concerns regarding the identifiability of human subjects from 
data released to the public, while addressed, were not 
                                                          
 300. Policies on Release of Human Genomic Sequence Data, Bermuda 
Quality Sequence, HUMAN GENOME PROJECT INFORMATION, 
http://www.ornl.gov/sci/techresources/Human_Genome/research/bermuda.sht
ml (last visited Oct. 28, 2010). 
 301. About the Human Genome Project, HUMAN GENOME PROJECT 
INFORMATION, 
http://www.ornl.gov/sci/techresources/Human_Genome/project/about.shtml 
(last visited Oct. 28, 2010). 
 302. See What is the HapMap, INTERNATIONAL HAPMAP PROJECT, 
http://hapmap.ncbi.nlm.nih.gov/thehapmap.html.en (last visited Oct. 28, 
2010). 
 303. Holden, supra note 147. 
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paramount in these early projects. 
In later projects, and particularly with the commencement 
of large-scale GWA studies, concerns with the potential 
identification of human subjects grew.304 The genotypic data 
generated by a GWA study is not meaningful without the 
associated phenotypic data. Because a GWA study often seeks 
to associate genotypic information (e.g., particular markers) 
with particular disease states, information regarding donor 
demographics, disease state and treatment are necessary to 
interpret the genotypic findings. The prospect of releasing 
clinical and phenotypic data to the public raised concern and 
led to the imposition of various policy restrictions on data users’ 
ability to disclose and transfer data, as well as the controlled-
access mechanisms enabled through repositories such as 
dbGaP.305 
2. Scientific Advancement and Publication Priority 
As discussed above, the more quickly scientific data is 
disseminated, the more quickly science will progress. 
Conversely, when the release of data is delayed due to the 
length of the publication cycle and patenting concerns, it can be 
argued that the progress of scientific advancement is retarded, 
or at least that it may not achieve its greatest potential. If data 
were not withheld until a researcher’s conclusions were 
published, but released prior to publication, the months-long 
delays associated with the publishing process could be avoided. 
Following this line of argument, in an ideal world, maximum 
scientific efficiency could be achieved by reducing the delay 
between data generation and data release to zero. That is, the 
most rapid pace of innovation, discovery of new therapies, 
development of new technologies, and understanding of natural 
phenomena could be achieved by releasing scientific data to the 
community the moment it is generated. 
Publication is, however, of crucial importance to scientific 
careers. Scientists typically spend months validating and 
analyzing their data, formulating hypotheses, re-running 
procedures, refining data, and then preparing the manuscript 
                                                          
 304. See Toronto Report, supra note 66, at 170. 
 305. For a general discussion of the protection of human subjects data in 
genomic studies, a topic that is beyond the scope of this paper but which has 
been extensively addressed in the literature, see for example, ANDREWS ET AL., 
supra note 75, at ch. 13; Crolla, supra note 75, at 241–47. 
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of the paper that will present their results to the community. 
What rational scientist would wish to give this data away 
before he or she has had a chance to analyze it? Why would he 
or she enable competitors who have done none of the work to 
benefit from the data to the same degree as he or she?306 Even 
Merton, who championed the norm of scientific communalism, 
did not specify how quickly the sharing of data should occur.307 
Thus, a clash of cultures has arisen, with the result being a 
heightened focus on the extent to which users of publicly 
released data may be restricted in their ability to present or 
publish results based on that data. The compromise in several 
recent cases has been time-based. That is, the “embargo” 
periods in the GAIN Policy, NIH GWAS Policy, and ENCODE 
2008 Policy all give users access to data and let them perform 
research, but prohibit them from making related presentations 
or submitting related papers during the embargo period.308 The 
approach taken by private consortia, in contrast, protects data 
generator priority by allowing data generators to retain data 
privately for a specified period. The trade-offs between these 
differing approaches is discussed below. 
3. Patent Encumbrances 
Patent protection is related to, but distinct from, the issue 
of publication priority. As discussed previously, early in the 
HGP, following the EST patenting debate, NIH representatives 
adopted a position that patent protection is inappropriate for 
DNA sequence information.309 This stance, also held by leaders 
of the scientific community and international funding agencies, 
is reflected in the Bermuda Principles.310 Accordingly, a 
number of the data release policies developed by private and 
academic consortia, such as those adopted by the International 
HapMap Consortium, GAIN, the SNP Consortium, and 
International SAE Consortium, take explicit steps to prevent 
                                                          
 306. See Eisenberg, Patents and Data-Sharing, supra note 47, at 1021 
(“Scientists who share their data promptly and freely may find themselves at a 
competitive disadvantage relative to free riders in the race to make and 
publish future observations . . . .”). 
 307. See Margo A. Bagley, Academic Discourse and Proprietary Rights: 
Putting Patents in their Proper Place, 47 B.C. L. REV. 217, 227 (2006) (quoting 
Robert K. Merton, The Normative Structure of Science, in THE SOCIOLOGY OF 
SCIENCE 274–75 (1973)). 
 308. Supra Table 1. 
 309. See supra notes 93–94 and accompanying text. 
 310. Contreras, Prepublication Data Release, supra note 5, at 393. 
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the patenting of results generated by their research.311 
NHGRI, however, must operate within the constraints of 
the Bayh-Dole Act.312 Thus, while NHGRI’s various post-
Bermuda data release policies all acknowledge the 
requirements of the Bayh-Dole Act, they demonstrate a general 
bias against the placement of patent encumbrances on genomic 
data.313 The enforceability, however, of policy provisions that 
merely “urge” or “encourage” data generators and users not to 
seek patents on inappropriate subject matter is open to some 
doubt.314 
Lacking a strong policy tool with which to limit expressly 
the patenting of genomic information, NHGRI policy makers 
have employed rapid pre-publication data release requirements 
as a surrogate for achieving the same result. In particular, the 
Bermuda Principles and their adoption and reaffirmation by 
NHGRI in 1997 and 2003, respectively, ensured that genomic 
data from the HGP and other large-scale sequencing projects 
would be made publicly-available before data generators had 
an opportunity to file patent applications covering any 
“inventions” arising from that data and in a manner that 
ensured its availability as prior art against third party patent 
filings at the earliest possible date.315 
When publication priority issues began to emerge with the 
movement toward GWAS and other studies involving 
phenotypic data components, the publication embargo was 
offered as a solution that both protected the publication 
interests of data generators, but still ensured the early release 
of data and, consequently, the patent-frustrating effects 
produced by the rapid pre-publication data release principles 
espoused by the Bermuda Principles. 
                                                          
 311. Supra Table 1. 
 312. NHGRI 1996 POLICY, supra note 107. 
 313. See ENCODE Pilot Policy, supra note 131; NHGRI 1996 POLICY, supra 
note 107 and accompanying text; NIH GWAS Policy, supra note 172. 
 314. See Rai & Eisenberg, supra note 106, at 309. 
 315. Interestingly, Rebecca Eisenberg suggests that, in some cases, the 
early release of experimental data may actually encourage more patent filings 
by third parties who are thereby enabled to combine public data with 
proprietary improvements and patent the combination thereof. See Eisenberg, 
supra note 47, at 1026. 
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V. CONCLUSION 
The twenty-year evolution of the genome commons 
illustrates the ways in which the distinct policy objectives of 
the relevant stakeholder communities have interacted over 
time to shape the formal and informal rules that govern the 
commons. Although governmental agencies played a significant 
role in the ongoing development of the policies governing the 
genome commons, other stakeholder groups including data 
generators, data users, and the public have strongly influenced 
the direction that these rules have taken. While the 
groundbreaking Bermuda Principles were straightforward in 
their implementation and effect, subsequent policies reflect an 
increased complexity that has arisen from the need to balance 
the competing and sometimes contradictory interests of these 
stakeholder groups.316 
The policy considerations described in this paper are by no 
means unique to the genome commons. Issues relating to the 
advancement of science, the appropriate level of patent 
protection for scientific discoveries, and value-maximizing 
rewards for researchers are pervasive in many fields of study. 
Thus, the lessons learned, and the compromises reached, by the 
designers of the genome commons can inform the discussion 
and analysis of scientific commons in a variety of fields. 
Moreover, as the genome commons continues to mature and 
expand into areas such as proteomics and metabolomics, the 
policies in existence today will likewise evolve. It is hoped that 
policy makers considering the design of new commons in these 
areas will look to the past to understand the complex 
compromises and rationales behind the policies that flowed 
from the Bermuda Principles, the legacy of which is likely to 
remain influential for years to come. 
                                                          
 316. For a discussion of the use of timing or “latency” variables as effective 
means for mediating among these competing stakeholder interests, see 
generally Contreras, Data Sharing, supra note 5. 
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APPENDIX – GLOSSARY OF TERMS 
CRP—Community Resource Project (description of a type 
of research project developed at the Ft. Lauderdale data release 
meeting) 
DAC—Data Access Committee 
dbGaP—Database of Genotypes and Phenotypes (database 
administered by the NIH’s National Library of Medicine) 
DDBJDNA—Databank of Japan (leading international 
DNA sequence repository) 
DOE—U.S. Department of Energy 
EMBL—European Molecular Biology Laboratory (leading 
European genomics research center and host of a large DNA 
sequence repository in Hinxton, England) 
ENCODE—Encyclopedia of DNA Elements (an NIH-
funded research project seeking to identify functional elements 
of the human genome) 
EST—Expressed Sequence Tag (a short fragment of DNA) 
GAIN—Genetic Association Information Network (a 
consortium formed to conduct GWA studies on six common 
human diseases) 
GWAS—Genome-Wide Association Study (a study that 
seeks genetic markers for specified physiological or pathological 
traits) 
GenBank—A publicly-accessible database of genetic 
sequences maintained by NCBI 
HGP—Human Genome Project (the U.S.-led international 
project to sequence the human genome) 
HIPAA—Health Insurance Portability and Accountability 
Act (U.S. legislation governing, among other things, privacy of 
patient healthcare data) 
HUGO—Human Genome Organisation (an international, 
policy-oriented group formed near the beginning of the HGP) 
Kb—Kilobase (unit of measurement equal to 1,000 DNA 
base pairs) 
MRC—UK Medical Research Council (principal medical 
funding agency in Britain) 
NAS—National Academy of Sciences (non-governmental 
agency that advises the U.S. government on scientific matters) 
NCBI—National Center for Biotechnology Information 
(NIH center that operates bioinformatics resources such as 
GenBank) 
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NCI—National Cancer Institute (NIH institute dedicated 
to cancer research, including cancer genomics) 
NHGRI—National Human Genome Research Institute (the 
principal U.S. funding agency for genomic research and one of 
the NIH institutes) 
NIH—National Institutes of Health (the principal U.S. 
funding agency for biomedical research, comprised of numerous 
different institutes) 
NRC—National Research Council of the U.S. National 
Academy of Sciences 
SNP—Single-Nucleotide Polymorphism (a “marker” in the 
genetic code) 
TCGA—The Cancer Genome Atlas (an NIH-funded pilot 
project relating to cancer genomics) 
WTCCC—Wellcome Trust Case Control Consortium (a 
large-scale UK-based GWA study) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
